<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
	<META HTTP-EQUIV="CONTENT-TYPE" CONTENT="text/html; charset=utf-8">
	<TITLE></TITLE>
	<META NAME="GENERATOR" CONTENT="LibreOffice 4.1.6.2 (Linux)">
	<META NAME="AUTHOR" CONTENT="Elle Saine">
	<META NAME="CREATED" CONTENT="20200409;224300000000000">
	<META NAME="CHANGEDBY" CONTENT="Cristina Aurrecoechea">
	<META NAME="CHANGED" CONTENT="20200409;224300000000000">
	<META NAME="AppVersion" CONTENT="16.0000">
	<META NAME="DocSecurity" CONTENT="0">
	<META NAME="HyperlinksChanged" CONTENT="false">
	<META NAME="LinksUpToDate" CONTENT="false">
	<META NAME="ScaleCrop" CONTENT="false">
	<META NAME="ShareDoc" CONTENT="false">
	<STYLE TYPE="text/css">
	<!--
		@page { size: 11in 8.5in; margin: 0.5in }
		P { margin-bottom: 0.08in; direction: ltr; widows: 2; orphans: 2 }
		A:link { color: #0563c1; so-language: zxx }
	-->
	</STYLE>
</HEAD>
<BODY LANG="en-US" LINK="#0563c1" DIR="LTR">

<style>

p {
  font-family: arial;
  font-size: 120%;
}
a { 
  text-decoration: none;
}
.summary-title {
  font-size: 1em;
  font-weight: bold;
}
details {
  margin: 1em 0;
}
details summary {
  font-size: 110%;
  margin-bottom: 1em;
}
details#references > summary::-webkit-details-marker { display: none; }

table {
  margin-left: auto;
  margin-right: auto;
  font-size: 110%;
}

</style>


<h1><A NAME="_GoBack"></A>Summaries of Current Research Data on SARS-CoV-2 - April 08, 2020</h1>
<BR>

<P STYLE="margin-bottom: 0in"><B>30-Thousand Foot View</B></P>
<P STYLE="margin-bottom: 0in"><I>This is intended to be as the
broadest sweeping summary for individuals to quickly reference of
both the evidence that supports use, as well as limitations &amp;/or
concerns. This can both be used in a newsletter-type document which
is sent to stakeholders to quickly review the current evidence (see
other document), as well as a reference page that links to more
in-depth information for each drug. Please note that I included links
to the other recommendation pages, consistent with the updated
guidelines.</I></P>
<P STYLE="margin-bottom: 0in"><BR>
</P>


<TABLE WIDTH=835 CELLPADDING=7 CELLSPACING=0>
	<COL WIDTH=263>
	<COL WIDTH=264>
	<COL WIDTH=263>
	<TR>
		<TD COLSPAN=3 WIDTH=819 HEIGHT=9 BGCOLOR="#808080" STYLE="border-top: 2.25pt solid #000001; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.01in"><a class="summary-title" href="#Hydroxychloroquine"><B>Hydroxychloroquine</a></P>
		</TD>
	</TR>
	<TR></TR>
	<TR>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Recommendation</B></FONT></P>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Evidence of
			Efficacy &amp;/or Effectiveness</B></FONT></P>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Limitations
			of Evidence</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Hydroxychloroquine&nbsp;400
				mg PO q12h x 1 day then 400 mg daily for 4 days can be considered
				in hospitalized and/or pregnant patients with COVID19.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Clinical
				data for hydroxychloroquine are limited. Patients with risk
				factors for progression to severe disease (immunocompromising
				conditions and medications, structural lung disease,
				hypertension, cardiovascular disease, diabetes, and age&nbsp;&gt;60
				years old) may also be at increased risk for side effects.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Not
				recommended for outpatient use as the risk outweighs the
				theoretical benefit, as patients cannot be closely monitored.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Consider
				with caution in patients with prolonged QT at baseline and/or
				other QT-prolonging medications. </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">A
				baseline ECG or review of telemetry tracing is recommended to
				assess QT in patients with age&gt;50, prior or current evidence
				of cardiac disease, or other agents that can prolong QT if an ECG
				has not been performed within the past 3 months or if changes
				have occurred in risk factors for QT prolongation since the last
				ECG. </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">If
				benefits of hydroxychloroquine outweigh risks in patients with
				prolonged QT or on other medications that prolong QT, reassess
				QTc by ECG or telemetry on or around day #3 of hydroxychloroquine
				in these high-risk patients. Ongoing monitoring may be needed at
				the discretion of the primary team. </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Low-risk
				patients do not need baseline ECG or ongoing monitoring unless
				otherwise dictated by clinical care.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Mixed
				evidence of efficacy against SARS-CoV-2 from two small randomized
				clinical trials in China. Among 62 patients (31 treated with
				hydroxychloroquine) hydroxychloroquine was associated with
				decreased duration of fever and cough.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">1</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">
				However, in a separate trial among 30 patients (15 treated with
				hydroxychloroquine) there was no difference in viral clearance
				between treatment and control.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">2</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Multiple
				clinical trials are ongoing.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Limited
				clinical data.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Two
				randomized clinical trials with small sample sizes demonstrated
				mixed evidence of efficacy against SARS-CoV-2.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
</TABLE>

<br><br>

<TABLE WIDTH=835 CELLPADDING=7 CELLSPACING=0>
	<COL WIDTH=263>
	<COL WIDTH=264>
	<COL WIDTH=263>
	<TR>
		<TD COLSPAN=3 WIDTH=819 HEIGHT=9 BGCOLOR="#808080" STYLE="border-top: 2.25pt solid #000001; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.01in"><a class="summary-title" href="#Chloroquine">Chloroquine</a></P>
		</TD>
	</TR>
	<TR></TR>
	<TR>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Recommendation</B></FONT></P>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Evidence of
			Efficacy &amp;/or Effectiveness</B></FONT></P>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Limitations
			of Evidence</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Not
				currently recommended as treatment for SARS-CoV-2.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">A
				clinical trial among 22 patients with SARS-CoV-2 found that
				patients treated with chloroquine (n=10) had viral clearance,
				improvement in chest CT, and faster discharge compared to
				patients treated with lopinavir/ritonavir (n=12).</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">3</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">
				</FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">A
				short communication describing a multicenter study in China found
				that chloroquine was superior to control in SARS-CoV-2.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">4</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">
				</FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt"><I>However,
				no methods, data, or analyses have been published.</I></FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">In
				vitro data suggests that chloroquine can inhibit SARS-CoV-2.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">5</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">
				 </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Animal
				models and in vitro studies against non-COVID19 coronaviruses
				show inhibitory effects of chloroquine, although these effects
				were dependent on both the timing of administration and the
				dose.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">6-13</FONT></FONT></SUP></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Only
				one small clinical trial has been published. </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Insufficient
				evidence to determine the efficacy of chloroquine against
				SARS-CoV-2.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Safety
				and efficacy have not been established in patients with COVID-19.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
</TABLE>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<TABLE WIDTH=835 CELLPADDING=7 CELLSPACING=0>
	<COL WIDTH=263>
	<COL WIDTH=264>
	<COL WIDTH=263>
	<TR>
		<TD COLSPAN=3 WIDTH=819 HEIGHT=9 BGCOLOR="#808080" STYLE="border-top: 2.25pt solid #000001; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.01in"><a class="summary-title" href="#HydroxychloroquinevsChloroquine">Hydroxychloroquine vs Chloroquine</a></P>
		</TD>
	</TR>
	<TR></TR>
	<TR>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Recommendation</B></FONT></P>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Evidence of
			Efficacy &amp;/or Effectiveness</B></FONT></P>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Limitations
			of Evidence</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">There
				is currently insufficient evidence to recommend the use of
				chloroquine over hydroxychloroquine against SARS-CoV-2. </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Mixed
				data from in vitro studies evaluating hydroxychloroquine and
				chloroquine against SARS-CoV-2. Conflicting findings regarding
				the comparative potency of the two drugs.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">14,15</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">
				Both drugs decreased viral replication in a dose-dependent
				manner.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">15</FONT></FONT></SUP></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">No
				clinical trial data.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Comparative
				effectiveness studies have not been conducted in patients with
				SARS-CoV-2.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
</TABLE>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<TABLE WIDTH=835 CELLPADDING=7 CELLSPACING=0>
	<COL WIDTH=263>
	<COL WIDTH=264>
	<COL WIDTH=263>
	<TR>
		<TD COLSPAN=3 WIDTH=819 HEIGHT=9 BGCOLOR="#808080" STYLE="border-top: 2.25pt solid #000001; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#00000a"><a class="summary-title" href="#AzithromycinHydroxychloroquine">Azithromycin + Hydroxychloroquine</a></P>
		</TD>
	</TR>
	<TR></TR>
	<TR>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Recommendation</B></FONT></P>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Evidence of
			Efficacy &amp;/or Effectiveness</B></FONT></P>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Limitations
			of Evidence</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Azithromycin
				should not be added to hydroxychloroquine only to treat
				SARS-CoV-2.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Single,
				non-randomized study</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">16,17</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">
				with 6/36 patients receiving hydroxychloroquine + azithromycin
				demonstrated improved virologic clearance among HCQ/azithro group
				(versus 14 HCQ and 16 control) at day 6. </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt"><I>However,
				the study had many important limitations in design and analysis.</I></FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">No
				randomized clinical trials.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Prospective
				case report among 11 hospitalized patients with severe COVID-19
				found no clinical benefit.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">18</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Previous
				research of macrolides in MERS-CoV demonstrated no benefit in
				mortality or viral clearance.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">19</FONT></FONT></SUP></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
</TABLE>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<TABLE WIDTH=835 CELLPADDING=7 CELLSPACING=0>
	<COL WIDTH=263>
	<COL WIDTH=264>
	<COL WIDTH=263>
	<TR>
		<TD COLSPAN=3 WIDTH=819 HEIGHT=9 BGCOLOR="#808080" STYLE="border-top: 2.25pt solid #000001; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.01in"><a class="summary-title" href="#Remdesivir">Remdesivir</a></P>
		</TD>
	</TR>
	<TR></TR>
	<TR>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Recommendation</B></FONT></P>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Evidence of
			Efficacy &amp;/or Effectiveness</B></FONT></P>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Limitations
			of Evidence</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Remdesivir
				is an investigational drug. </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Treat
				is among non-critically ill hospitalized patients is through
				clinical trials with Remdesivir,&nbsp;if the patient qualifies
				(dosing and duration depend on clinical trial). </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Remdesivir
				can be prescribed as compassionate use in pregnancy (200 mg IV x
				1 day then 100 mg IV daily for total 10-14 days); however, safety
				data of remdesivir in pregnant humans is minimal so decision to
				use remdesivir should be made in conjunction with Maternal Fetal
				Medicine and Infectious Diseases, as well as shared decision
				making with the patient. Compassionate use remdesivir is not an
				FDA-approved medication and should be obtained only through
				infectious diseases consultation.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">If
				you think a patient would qualify for a remdesivir trial, please
				directly contact Kathleen Degnan (HUP) or William Short (PPMC).
				Do not alter patient treatment or testing based on the
				possibility of trial enrollment. Trials are available only if the
				patient is an inpatient at HUP or PPMC.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">In
				SARS-CoV-2, evidence is from a single case report among one
				patient</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">20</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">
				and an in vitro study.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">5</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Several
				trials are currently underway investigating in vivo use in
				SARS-CoV-2.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Animal
				models and in vitro studies in SARS-CoV-1 and MERS-CoV indicate
				that Remdesivir reduces viral replication and improves clinical
				outcomes.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">21-23</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Animal
				studies in SARS-CoV indicate that timing of administration early
				in course may maximize potential benefit.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">23</FONT></FONT></SUP></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Inadequate
				evidence in SARS-CoV-2.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Inadequate
				in vivo evidence in MERS &amp; SARS-CoV-1.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">A
				clinical trial investigating remdesivir in Ebola was discontinued
				early after demonstrating a decreased mortality benefit relative
				to other investigational drugs.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">24</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Limited
				evidence in pregnancy.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
</TABLE>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<TABLE WIDTH=835 CELLPADDING=7 CELLSPACING=0>
	<COL WIDTH=263>
	<COL WIDTH=264>
	<COL WIDTH=263>
	<TR>
		<TD COLSPAN=3 WIDTH=819 HEIGHT=9 BGCOLOR="#808080" STYLE="border-top: 2.25pt solid #000001; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.01in"><a class="summary-title" href="#Ribavirin">Ribavirin</a></P>
		</TD>
	</TR>
	<TR></TR>
	<TR>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Recommendation</B></FONT></P>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Evidence of
			Efficacy &amp;/or Effectiveness</B></FONT></P>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Limitations
			of Evidence</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">In
				critically-ill patients, may consider adding Ribavirin 2g PO x 1
				then 600 mg PO q8h to Lopinavir/ritonavir&nbsp;400 mg/100mg PO
				q12h x 10-14 days. </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Not
				currently recommended as monotherapy for SARS-CoV-2.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Ribavirin
				is contraindicated in pregnancy, males with pregnant partners,
				and in patients with hemoglobinopathies.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Ribavirin
				carries a risk of hemolytic anemia, which can be severe.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Mixed
				evidence from retrospective studies in MERS. One retrospective
				study among 44 patients treated with ribavirin + interferon-a-2a
				saw a reduction in 14 day mortality, but not 28 day mortality.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">25</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">
				However, two other studies found no difference in mortality or
				viral clearance.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">26,27</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Open
				trial data among 152 patients with MERS demonstrated benefit of
				lopinavir/ritonavir in combination with ribavirin over ribavirin
				alone.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">28</FONT></FONT></SUP></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">There
				currently is no in vitro or clinical data available for ribavirin
				against SARS-CoV-2.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Little
				to no data showing benefit when used as monotherapy or with
				interferon.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">One
				study among 90 patients with SARS-CoV-1 found no benefit with
				ribavirin compared to antibiotics and steroids.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">29</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Mixed
				evidence from retrospective studies in MERS. Two studies among 5
				and 349 patients with MERS demonstrated no difference in
				mortality or viral clearance.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">26,27</FONT></FONT></SUP></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
</TABLE>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<TABLE WIDTH=835 CELLPADDING=7 CELLSPACING=0>
	<COL WIDTH=263>
	<COL WIDTH=264>
	<COL WIDTH=263>
	<TR>
		<TD COLSPAN=3 WIDTH=819 HEIGHT=9 BGCOLOR="#808080" STYLE="border-top: 2.25pt solid #000001; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.01in"><a class="summary-title" href="#LopinavirRitonavir">Lopinavir/Ritonavir</a></P>
		</TD>
	</TR>
	<TR></TR>
	<TR>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Recommendation</B></FONT></P>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Evidence of
			Efficacy &amp;/or Effectiveness</B></FONT></P>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Limitations
			of Evidence</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">In
				critically ill patients, may consider Lopinavir/ritonavir&nbsp;400
				mg/100mg PO q12h x 10-14 days +/-&nbsp;Ribavirin2g PO x 1 then
				600 mg PO q8h</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Assess
				for drug-drug interactions before starting. Main side effect is
				GI intolerance. Monitor LFTs while on therapy.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Administer
				with food for optimal absorption.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Liquid
				formulation is reserved for patients without oral access or
				ability to swallow tablets. Liquid formulation should be
				administered only through PVC- or silicone-based feeding tubes.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Crushing
				tablets is not recommended due to 50% reduction in exposure and
				should only be considered if no other options are available and
				after consulting with an infectious diseases specialist.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">A
				retrospective study among 33 patients with COVID-19 in China
				found that combined lopinavir/ritonavir + arbidol (n=16) was
				associated with clinical improvement and decreased viral
				detectability when compared to lopinavir/ritonavir (n=17)
				alone.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">30</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">A
				retrospective cohort study among patients with SARS-CoV-1 in Hong
				Kong found improved mortality and decreased intubation rates
				among patients who received lopinavir/ritonavir + ribavirin
				(n=75) as initial treatment, compared to control (n=634). </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt"><I>No
				difference was found when lopinavir/ritonavir + ribavirin was
				used as salvage therapy.</I></FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">31</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Animal
				and in vitro studies in SARS-CoV-1 and MERS found improved
				clinical and virologic response with lopinavir/ritonavir compared
				to control.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">28,32</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">
				</FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">In
				a randomized clinical trial among 199 patients with SARS-CoV-2 in
				China, there was no difference in mortality, time to clinical
				improvement, or viral clearance among patients who receive
				lopinavir/ritonavir (n=99) compared to control (n=100).</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">33</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">A
				case series among 18 patients with COVID-19 in Singapore found
				equivocal data on clinical outcomes and viral shedding among 5
				patients receiving lopinavir/ritonavir. </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt"><I>4/5
				patients discontinued treatment early due to side effects.</I></FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">34</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Animal
				and in vitro studies in SARS-CoV-1 and MERS found that lopinavir
				and ritonavir were not as efficacious when administered
				individually.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">35,36</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">In
				comparison to remdesivir, combined lopinavir, ritonavir and
				interferon beta had decreased antiviral efficacy against MERS-CoV
				in vitro and in vivo.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">22</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">
				</FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
</TABLE>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<TABLE WIDTH=835 CELLPADDING=7 CELLSPACING=0>
	<COL WIDTH=263>
	<COL WIDTH=264>
	<COL WIDTH=263>
	<TR>
		<TD COLSPAN=3 WIDTH=819 HEIGHT=9 BGCOLOR="#808080" STYLE="border-top: 2.25pt solid #000001; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.01in"><a class="summary-title" href="#Corticosteroids">Corticosteroids</a></P>
		</TD>
	</TR>
	<TR></TR>
	<TR>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Recommendation</B></FONT></P>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Evidence of
			Efficacy &amp;/or Effectiveness</B></FONT></P>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Limitations
			of Evidence</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Not
				recommended as treatment for SARS-CoV-2. Corticosteroids may
				worsen outcomes and prolong duration of viral shedding. However,
				they could be considered if patient has another compelling
				indication.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P ALIGN=LEFT STYLE="margin-right: 0.17in; margin-bottom: 0.04in">
				<FONT COLOR="#000000"><FONT SIZE=2><FONT COLOR="#00000a"><FONT SIZE=2 STYLE="font-size: 9pt">Betamethasone&nbsp;12mg
				IM Q24H x 2 doses for fetal lung maturity may be considered in
				cases at very high risk of preterm delivery before 34 weeks.
				These cases should be reviewed with Maternal Fetal Medicine prior
				to administration of betamethasone.</FONT></FONT></FONT></FONT></P>
			</UL>
			<P ALIGN=JUSTIFY STYLE="margin-right: 0.17in"><BR>
			</P>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">A
				retrospective cohort study among COVID-19 patients who developed
				ARDS (n=84) found that methylprednisolone treatment was
				associated with a decreased risk of death.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">37</FONT></FONT></SUP></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 2.25pt solid #000001; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">No
				clinical trial data in SARS-CoV-2.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">currently
				no definite evidence of benefit</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Descriptive
				studies of corticosteroids in SARS-CoV-2 do not suggest a clear
				benefit.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">38,39</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Studies
				of corticosteroids in treating other viral illnesses including
				MERS, SARS, and influenza found no mortality benefit and noted
				reduced viral clearance in addition to other known corticosteroid
				side effects.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">40-42</FONT></FONT></SUP></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
</TABLE>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<TABLE WIDTH=835 CELLPADDING=7 CELLSPACING=0>
	<COL WIDTH=263>
	<COL WIDTH=264>
	<COL WIDTH=263>
	<TR>
		<TD COLSPAN=3 WIDTH=819 HEIGHT=9 BGCOLOR="#808080" STYLE="border-top: 2.25pt solid #000001; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.01in"><FONT COLOR="#00000a"><a class="summary-title" href="#Tocilizumab">Tocilizumab</a></FONT></P>
		</TD>
	</TR>
	<TR></TR>
	<TR>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2 STYLE="font-size: 9pt"><B>Recommendation</B></FONT></P>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: 0.05in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt"><B>Evidence
			of Efficacy &amp;/or Effectiveness</B></FONT></FONT></FONT></FONT></FONT></P>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 2.25pt solid #000001; border-bottom: 1px solid #00000a; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: 0.17in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt"><B>Limitations
			of Evidence</B></FONT></FONT></FONT></FONT></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Not
				currently recommended as part of treatment for SARS-CoV2</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=264 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">Single,
				retrospective, single arm, observational study of 21 patients in
				China showed improvement of fever, oxygenation, and chest
				imaging. </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt"><I>However,
				this study has many important design limitations and a number of
				confounding variables.</I></FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">4
				case reports, to date, demonstrating predominantly good outcomes
				in patients receiving tocilizumab for other indications.</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">43-46</FONT></FONT></SUP></FONT></FONT></FONT></P>
			</UL>
		</TD>
		<TD WIDTH=263 STYLE="border-top: 1px solid #00000a; border-bottom: 2.25pt solid #000001; border-left: 1px solid #00000a; border-right: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2 STYLE="font-size: 9pt">No
				randomized clinical trial data (1 ongoing in China)</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
</TABLE>



<!-- ================================  GROUND LEVEL VIEW ================= -->
<P STYLE="margin-bottom: 0in"><BR>
</P>
<P STYLE="margin-bottom: 0in"><BR>
</P>
<P STYLE="margin-bottom: 0in"><B>Ground-level View</B></P>
<P STYLE="margin-bottom: 0in"><I>This view is intended to be in-depth
summaries of all of the data. Each study will be presented in a
standardized way of the question, design, outcome under evaluation,
participants, findings, and limitations in interpretation. This is
meant to be the data that can be linked to from overview pages.</I></P>


<details>
<summary><a name="Hydroxychloroquine">Hydroxychloroquine</a></summary>

<TABLE WIDTH=88% CELLPADDING=7 CELLSPACING=0>
	<COL WIDTH=38*>
	<COL WIDTH=218*>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=9 BGCOLOR="#212f57" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Hydroxychloroquine</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=3 VALIGN=TOP BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Mechanism: </B></FONT><FONT SIZE=2>Metabolite
			of chloroquine. Anti-malarial 4-aminoquinoline&nbsp;</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=5 BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Experimental
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#00000a"><FONT SIZE=2><B>Chen Z, Hu
			J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with
			COVID-19: results of a randomized clinical trial. </B></FONT></FONT><FONT COLOR="#00000a"><FONT SIZE=2><I><B>medRxiv.
			</B></I></FONT></FONT><FONT COLOR="#00000a"><FONT SIZE=2><B>2020:2020.2003.2022.20040758.</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Is hydroxychloroquine (HCQ) efficacious in
			treatment of patients with COVID-19?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<OL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Compared
				to standard treatment, patients receiving HCQ had a significant
				reduction in duration of fever (3.2 days vs. 2.2 days) and cough</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Compared
				to control group, a larger proportion of patients in the control
				group had improvement in pneumonia on imaging between days 0 and
				6 (54.8% vs. 80.6%) </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Two
				patients in HCQ group had mild adverse events</FONT></FONT></FONT></FONT></FONT></P>
			</OL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Randomized
			(double-blinded) clinical trial of patients with COVID-19 in
			Wuhan, China</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>62
				patients received standard treatment: oxygen therapy, antiviral
				agents, antibacterial agents, and immunoglobulin, +/-
				corticosteroids </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				group (N=31): additionally received 5 days of </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>hydroxychloroquine
				400 mg daily</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Control
				group (N=31): standard treatment, only</FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>
				</FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Time
				to clinical recovery and clinical characteristics 5 days after
				enrollment</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Change
				in Chest CT between day 0 and day 6</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>62 patients admitted
			with RT-PCR confirmed COVID-19 and pneumonia on chest CT at Renmin
			Hospital, Wuhan University</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Inclusion
				criterial: Age ≥ 18 years; SaO2/SPO2 ratio &gt; 93% or
				PaO2/FIO2 ratio &gt; 300 </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exclusion
				criteria: Does not meet safe follow-up criteria due to severe and
				critical illness or safety concerns; retinal diseases;
				arrhythmias; Severe liver disease (e.g., Child-Pugh score C or
				AST&gt; twice the upper limit); Pregnant or breastfeeding; Severe
				renal failure [GFR &lt; 30 mL/min] or receiving renal replacement
				therapy; possibility of being transferred to another hospital
				within 72 hours; received any trial treatment for COVID-19 within
				30 days </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>A large proportion of screened participants were
			excluded, no measure of viral load. Choice of endpoints suboptimal
			&amp; poor reporting</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Chen Jun LD, Liu Li, Liu Ping, Xu
			Qingnian, Xia Lu, Ling Yun, Huang Dan, Song Shuli, Zhang Dandan,
			Qian Zhiping, Li Tao, Shenn Yinzhong, Lu Hongzhou. A pilot study
			of hydroxychloroquine in treatment of patients with common
			coronavirus disease-19 (COVID-19). </B></FONT><FONT SIZE=2><I><B>J
			Zhejiang Univ (Med Sci). </B></I></FONT><FONT SIZE=2><B>2020;49(1):0-0.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=3 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Is hydroxychloroquine (HCQ) safe &amp; efficacious
			in the treatment of patients with COVID-19?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>No difference between
			treatment and control group</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>At
				day 7, there was no significant difference in viral clearance
				between treatment and control group (93% vs. 87%; P&gt;0.05), as
				measured by nasopharyngeal swab </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				difference median hospital duration, time to become afebrile, or
				adverse events (diarrhea, LFT abnormality)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>At
				two weeks no deaths in any patients.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P><FONT SIZE=2>Radiologic progression in CT in 33.3% HCQ group
			and 46.7% control group</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT COLOR="#000000"><FONT SIZE=2>Randomized
			clinical trial among 30 patients with COVID-19 at the Shanghai
			</FONT></FONT><FONT SIZE=2>Public Health Clinical Center in China</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				group (N=15): 5 days of </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>hydroxychloroquine
				400 mg daily</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Control
				group (N=15): conventional treatment, only</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=6 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Viral carriage in respiratory phalangeal swab at
			day 7</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=4 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>30 treatment naïve patents hospitalized at
			Shanghai Public Health Clinical Center in China</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Details taken from abstract as paper was not in
			English</FONT></P>
		</TD>
	</TR>
</TABLE>

</details>

<details>
<summary><a name="Chloroquine">Chloroquine</a></summary>

<TABLE WIDTH=88% CELLPADDING=7 CELLSPACING=0>
        <COL WIDTH=38*>
        <COL WIDTH=218*>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#212f57" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Chloroquine</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 VALIGN=TOP BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT COLOR="#00000a"><FONT SIZE=2><B>Mechanism:</B></FONT></FONT><FONT SIZE=2>
			Against Coronavirus: Alkalize the phagolysosome, which hampers the
			low pH-dependent steps of viral replication, including infusion
			and uncoating. Other mechanisms are poorly explained.</FONT><SUP><FONT SIZE=2>
			</FONT></SUP><FONT SIZE=2>Interferes with glycosylation of
			cellular receptors of SARS-CoV.</FONT><FONT COLOR="#00000a"><SUP><FONT SIZE=2>5,47</FONT></SUP></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=5 BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Experimental
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Gao J, Tian Z, Yang X.
			Breakthrough: Chloroquine phosphate has shown apparent efficacy in
			treatment of COVID-19 associated pneumonia in clinical studies.
			</B></FONT><FONT SIZE=2><I><B>Biosci Trends. </B></I></FONT><FONT SIZE=2><B>2020;14(1):72-73.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Short communication describing multicenter trial
			to evaluate the safety and efficacy of chloroquine phosphate in
			coronavirus pneumonia</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Results have
			demonstrated that chloroquine phosphate is superior to control
			treatment in inhibiting the exacerbation of pneumonia, improving
			lung imaging findings, promoting a virus negative conversion, and
			shortening disease course</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				adverse events noted</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Chloroquine
				was recommended for inclusion in the next version of the
				Guidelines for the Prevention, Diagnosis, and Treatment of
				Pneumonia Caused by COVID-19 issued by the National Health
				Commission of the People's Republic of China </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Brief communication regarding 20 ongoing clinical
			trials across 10 hospitals in Wuhan, Jingzhou, Guangzhou, Beijing,
			Shanghai, Chongqing, and Ningbo, China to evaluate the efficacy
			and safety of chloroquine and hydroxychloroquine</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Communication of preliminary findings from ongoing
			clinical trials in China</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>100 patients across 10 hospitals</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Review article: no data
			or analyses presented</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Study
				design, analyses, and validity of findings are not able to be
				evaluated</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Hong W. Combating COVID-19 with
			Chloroquine. </B></FONT><FONT SIZE=2><I><B>J Mol Cell Biol. </B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does chloroquine have a therapeutic benefit among
			patients with COVID19?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Chloroquine was
			effective among patients with SARS-CoV-2</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Percentage
				of patients who transitioned to a negative PCR were slightly
				higher at day 7, 10, and 14 in chloroquine group</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>On
				chest CT, more improvement was noted in the chloroquine group. </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patients
				were discharged faster in chloroquine group</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>On
					day 14, 10/10 (100%) patients in the chloroquine group were
					discharged, compared to  6/12 (50%) patients in the
					lopinavir/ritonavir group</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Clinical trial among 22
			patients in Singapore with SARS-CoV-2 positive PCR treated with
			either chloroquine or lopinavir/ritonavir for 10 days and
			followed-up for a total of 14 days</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>10
				patients (3 severe, 7 moderate) received 10 days chloroquine
				500mg twice daily</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>12
				patients (5 severe, 7 moderate) received 10 days of
				lopinavir/ritonavir 400mg/100mg bid</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Viral RNA by RT-PCR, lung function by computerized
			tomography (CT) scanning, and T cell counts </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>22 patients with SARS-CoV-2</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Small sample size</FONT></P>
			<P><FONT SIZE=2>Baseline characteristics and statistical analyses
			were not presented</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>In Vitro </B></FONT></FONT>
			</P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Wang M, Cao R, Zhang L, et al.
			Remdesivir and chloroquine effectively inhibit the recently
			emerged novel coronavirus (2019-nCoV) in vitro. </B></FONT><FONT SIZE=2><I><B>Cell
			Res. </B></I></FONT><FONT SIZE=2><B>2020;30(3):269-271.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does chloroquine have in vitro antiviral efficacy
			against a clinical isolate of SARS-CoV-2? </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Demonstration of
			efficacy of chloroquine in vitro against SARS-CoV-2</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>In
				vitro activity of chloroquine against 2019-nCoV in monkey kidney
				cells at low- micromolar concentrations (half-maximal effective
				concentration [EC</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>],
				–1.13 mM; EC</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>90</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>
				was 6.90 mM) high  cytotoxicity (cytotoxic concentration
				[CC</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>],&gt;100),
				and high selectivity (selectivity  index [SI], &gt;88.5)
				suggesting effective concentration likely to be achieved in
				non-human primates</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>EC</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>90
					</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>can
					be clinically achievable as demonstrated in plasma of RA
					patients who received 500 mg</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Time
				of addition assay demonstrated chloroquine functioned at both
				entry and at post-entry stages of the 2019-nCoV infection in Vero
				E6 cells</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>In vitro study evaluating Vero E6 cells
			(ATCC-1586) infected with 2019-nCoV (clinical isolate
			nCoV-2019BetaCoV/Wuhan/WIV04/2019) at a MOI of 0.05 and then
			treated with different doses of antiviral</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro antiviral
			efficacy:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Mean
				inhibition of virus yield (quantified by qRT-PCR) and
				cytotoxicity (CCK-8 assay)</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P><FONT SIZE=2>Determination of when Remdesivir acts, relative to
			viral entry, using a time-of-addition assay</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro cell lines:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>African
				green monkey kidney Vero E6 cell line </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Human
				liver cancer Huh7 cell line </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Difficult to extrapolate in vivo activity and
			dosing from in vitro experiments</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Evidence in
			Other Coronaviruses&nbsp;</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Barnard DL, Day CW, Bailey K, et
			al. Evaluation of immunomodulators, interferons and known in vitro
			SARS-coV inhibitors for inhibition of SARS-coV replication in
			BALB/c mice. </B></FONT><FONT SIZE=2><I><B>Antivir Chem Chemother.
			</B></I></FONT><FONT SIZE=2><B>2006;17(5):275-284.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=3 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does chloroquine reduce the replication of
			SARS-CoV in vivo?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=3 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro: Chloroquine
			inhibited virus replication (IC</FONT><SUB><FONT SIZE=2>90</FONT></SUB><FONT SIZE=2>,
			11)</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Found
				to be more toxic than has been previously reported</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P><FONT SIZE=2>In vivo: Chloroquine did not significantly reduce
			the replication of SARS-CoV virus in the lungs of infected mice</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro study
			evaluating Vero 76 cells infected with SARS-CoV, strain Urbani
			(200300592), and treated with different doses of antiviral</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo study mice were
			pretreated with chloroquine and then exposed to SARS-CoV, strain
			Urbani (200300592) </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Toxicity-controlled
				with</FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2> </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>five
				mice treated at each dose of compound or placebo</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Lungs
				were assayed for viral titer</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=2 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>90% reduction in virus yield (IC</FONT><SUB><FONT SIZE=2>90</FONT></SUB><FONT SIZE=2>)
			</FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>African green monkey
			kidney cells (Vero 76) </FONT>
			</P>
			<P><FONT SIZE=2>Specific pathogen-free BALB/c female mice </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Difficult to
			extrapolate in vivo activity and dosing from in vitro experiments</FONT></P>
			<P><FONT SIZE=2>Animal models are an imperfect analog to humans</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Burkard C, Verheije MH, Wicht O,
			et al. Coronavirus Cell Entry Occurs through the Endo-/Lysosomal
			Pathway in a Proteolysis-Dependent Manner. </B></FONT><FONT SIZE=2><I><B>PLOS
			Pathogens. </B></I></FONT><FONT SIZE=2><B>2014;10(11):e1004502.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>How do coronaviruses enter the host cell membrane?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Inhibition of endosome
			maturation with chloroquine severely diminished luciferase
			expression when the inhibitors were added prior to infection</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Much
				smaller effects were observed when chloroquine was added at 2hpi</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>The
					inhibitors (chloroquine) mainly affect MHV entry. </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro use of
			recombinant mouse hepatitis coronavirus (MHV) expressing reporter
			genes and a novel replication-independent fusion assay to
			investigate fusion and entry. </FONT>
			</P>
			<P><FONT SIZE=2>Perturbation of endosome maturation by the
			addition of inhibitory agents (chloroquine) corroborated the
			importance of trafficking of MHV virions through the endocytic
			pathway.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Determine cell entry pathway</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>HeLa-mCC1a cells </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Difficult to extrapolate in vivo activity and
			dosing from in vitro experiments</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>de Wilde AH, Jochmans D, Posthuma
			CC, et al. Screening of an FDA-approved compound library
			identifies four small-molecule inhibitors of Middle East
			respiratory syndrome coronavirus replication in cell culture.
			</B></FONT><FONT SIZE=2><I><B>Antimicrob Agents Chemother.
			</B></I></FONT><FONT SIZE=2><B>2014;58(8):4875-4884.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=2 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does chloroquine exhibit anti-MERS-CoV activity?</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD WIDTH=15% HEIGHT=10 VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Chloroquine inhibited
			MERS replication in a dose-dependent manner in the low-micromolar
			range (EC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>
			3mM), inhibited SARS replication with EC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>
			4.1mM, and inhibited human coronavirus 229E with EC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>
			3.3mM</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Chloroquine
				blocked MERS entry at an early step. </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD WIDTH=15% HEIGHT=10 VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>In vitro study of cells infected with MERS-CoV
			(strain EMC/2012), SARS-CoV, and HCoV-229E, followed by screening
			of 348 FDA-approved drugs.</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD WIDTH=15% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>50% effective concentration (EC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>)
			and compound-specific toxicity (50% cytotoxic concentration
			[CC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>]) </FONT>
			</P>
		</TD>
	</TR>
	<TR>
		<TD WIDTH=15% HEIGHT=10 VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vero, Vero E6, and Huh7
			cells </FONT>
			</P>
			<P><BR>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=3 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Difficult to extrapolate in vivo activity and
			dosing from in vitro experiments</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Keyaerts E, Vijgen L, Maes P,
			Neyts J, Van Ranst M. In vitro inhibition of severe acute
			respiratory syndrome coronavirus by chloroquine. </B></FONT><FONT SIZE=2><I><B>Biochem
			Biophys Res Commun. </B></I></FONT><FONT SIZE=2><B>2004;323(1):264-268.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=2 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does chloroquine inhibit of the replication
			SARS-CoV in vitro ?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Chloroquine inhibited
			SARS-CoV in Vero E6 cells </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>IC</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>
				of chloroquine for antiviral activity (8.8 ± 1.2 lM) was
				significantly lower than its cytostatic activity; CC50 (261.3 ±
				14.5 lM), with a selectivity index of 30</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Chloroquine
				administration could be delayed for up to 5 hours
				pos-inoculation, without a significant drop in antiviral activity
				</FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>In vitro study evaluating Vero E6 cells infected
			with SARS-CoV-2 and then treated with different doses of antiviral</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=3 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Cytostatic activity of chloroquine</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Vero E6 cells</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Difficult to
			extrapolate in vivo activity and dosing from in vitro experiments</FONT></P>
			<P><FONT SIZE=2>Animal models are an imperfect analog to humans</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Keyaerts E, Li S, Vijgen L, et al.
			Antiviral activity of chloroquine against human coronavirus OC43
			infection in newborn mice. </B></FONT><FONT SIZE=2><I><B>Antimicrob
			Agents Chemother. </B></I></FONT><FONT SIZE=2><B>2009;53(8):3416-3421.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Can chloroquine prevent in vitro replication of
			human corona virus and death in mice?</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD WIDTH=15% HEIGHT=10 VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro: Chloroquine
			inhibited HCoV-OC43 replication in HRT-18 cells, with an EC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>
			of 0.306 mM </FONT>
			</P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo: Chloroquine,
			acquired transplacentally or via maternal milk, prevented
			HCoV-OC43-induced death in newborn mice</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Survival
				rates declined in a dose-dependent manner: Highest survival rate
				(98.6%) when mother mice were treated daily with a concentration
				of 15 mg/kg chloroquine, 88% survival when treated with 5 mg/kg,
				13% survival when treated with 1 mg/kg</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD WIDTH=15% HEIGHT=10 VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro study
			evaluating HRT-18 cells infected with HCoV-OC43 and treated with
			different doses of antiviral</FONT></P>
			<P><FONT SIZE=2>In vivo study of female pregnant mice injected
			subcutaneously different dilutions of chloroquine beginning 2 days
			before labor, with subsequent inoculation of five-day old mice </FONT>
			</P>
		</TD>
	</TR>
	<TR>
		<TD WIDTH=15% HEIGHT=10 VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Viral replication</FONT></P>
			<P><FONT SIZE=2>Death of mice pups</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD WIDTH=15% HEIGHT=10 VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>HRT-18 cells </FONT>
			</P>
			<P><FONT SIZE=2>Five-day old pups born from six-week-old male and
			female C57BL/6 mice </FONT>
			</P>
		</TD>
	</TR>
	<TR>
		<TD WIDTH=15% HEIGHT=10 VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Difficult to
			extrapolate in vivo activity and dosing from in vitro experiments</FONT></P>
			<P><FONT SIZE=2>Animal models are an imperfect analog to humans</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Kono M, Tatsumi K, Imai AM, Saito
			K, Kuriyama T, Shirasawa H. Inhibition of human coronavirus 229E
			infection in human epithelial lung cells (L132) by chloroquine:
			involvement of p38 MAPK and ERK. </B></FONT><FONT SIZE=2><I><B>Antiviral
			Res. </B></I></FONT><FONT SIZE=2><B>2008;77(2):150-152.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does chloroquine have antiviral effects of on
			human coronavirus 229E (HCoV-229E) infection of human fetal lung?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Significantly decreased
			the viral replication at concentrations lower than in clinical
			usage </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Affected
				activation of p38 mitogen-activated protein kinase and
				extracellular signal-regulated kinase </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P><FONT SIZE=2>Inhibited the release of HCoV- 229E into
			supernatants significantly in a dose-dependent manner </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Using human fetal lung cell lines infected with
			HCoV-229E and treated with varying doses of antiviral.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=4 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Viral replication</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Human fetal lung cell lines</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Difficult to extrapolate in vivo activity and
			dosing from in vitro experiments</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Takano T, Katoh Y, Doki T,
			Hohdatsu T. Effect of chloroquine on feline infectious peritonitis
			virus infection in vitro and in vivo. </B></FONT><FONT SIZE=2><I><B>Antiviral
			Res. </B></I></FONT><FONT SIZE=2><B>2013;99(2):100-107.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=3 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does chloroquine inhibited FIPV replication in
			vitro and in cats with experimentally induced FIP?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro: Chloroquine
			had an inhibitory effect against the replication of FIP virus in
			vitro</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Demonstrated
				inhibitory and anti-inflammatory effect of chloroquine versus FIP</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo: Cats receiving
			chloroquine had better clinical course than untreated cats </FONT>
			</P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Alanine
				aminotransferase levels increased in the chloroquine-treated
				groups. </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro: feline
			monocytes cultured chloroquine for two days </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Virus
				titers and TCID</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>
				were calculated </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Cytokine
				mRNA, and FCoV N genes were measured</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Nine specific
			pathogen-free (SPF) cats randomly assigned to three experimental
			groups: </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Early
				group: chloroquine (10 mg/kg) subcutaneously administered prior
				to FIPV inoculation</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Late
				group: saline subcutaneously administered prior to FIPV
				inoculation, with chloroquine (10 mg/kg) after inoculation</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Control:
				saline subcutaneously administered prior to and after FIPV
				inoculation</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>One
					cat in the control group died prior to FIPV inoculation and was
					excluded</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Clinical signs, and we measured their body
			temperature and weight</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Felis catus whole
			fetus-4 (fcwf-4) cells </FONT>
			</P>
			<P><FONT SIZE=2>Nine SPF cats</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Difficult to
			extrapolate in vivo activity and dosing from in vitro experiments</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Animal models are an
			imperfect analog to humans</FONT></P>
			<P><FONT SIZE=2>FIP is caused by a feline strain of coronavirus</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-bottom: 0in"><FONT SIZE=2><B>Vincent
			MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent
			inhibitor of SARS coronavirus infection and spread. </B></FONT>
			</P>
			<P ALIGN=CENTER><FONT SIZE=2><I><B>Virol J. </B></I></FONT><FONT SIZE=2><B>2005;2:69-69.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=1 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does chloroquine inhibit SARS-CoV?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Chloroquine was
			effective in inhibiting the infection and spread of SARS CoV in
			cell cultures in a dose-dependent manner</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Had
				significant inhibitor effect when susceptible cells were treated
				either before or after infection, suggesting possible prophylaxis
				and treatment use </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=6 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Cells were treated with various doses of antiviral
			(pre- and post-infection) and exposed to SARS-CoV.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Proportion of virus-antigen-positive cells.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Vero E6 cells </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=6 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Difficult to extrapolate in vivo activity and
			dosing from in vitro experiments</FONT></P>
		</TD>
	</TR>


</TABLE>
</details>

<details>
<summary><a name="HydroxychloroquinevsChloroquine">Hydroxychloroquine vs Chloroquine</a></summary>

<TABLE WIDTH=88% CELLPADDING=7 CELLSPACING=0>
        <COL WIDTH=38*>
        <COL WIDTH=218*>

	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#212f57" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Hydroxychloroquine
			vs Chloroquine</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=5 BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>In Vitro</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.07in; text-indent: 0.07in"><FONT SIZE=2><B>Liu
			J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative
			of chloroquine, is effective in inhibiting SARS-CoV-2 infection in
			vitro. </B></FONT><FONT SIZE=2><I><B>Cell Discov. </B></I></FONT><FONT SIZE=2><B>2020;6:16.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=4 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Is hydroxychloroquine as efficacious as
			chloroquine in treating SARS-CoV-2 infection?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Hydroxychloroquine can
			efficiently inhibit SARS-CoV-2 infection in vitro </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>There
				was no significant difference in the cytotoxic concentration
				(CC</FONT></FONT></FONT><FONT COLOR="#000000"><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB></FONT><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>)
				of </FONT></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>hydroxychloroquine
				and chloroquine (</FONT></FONT></FONT><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>273.3
				vs. 249.5)</FONT></FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The anti-SARS-CoV-2
			activity of hydroxychloroquine may be less potent compared to
			chloroquine </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>At
				all MOIs (0.01, 0.02, 0.2, and 0.8), the EC</FONT></FONT></FONT><FONT COLOR="#000000"><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB></FONT><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>
				for chloroquine (2.71, 3.81, 7.14, and 7.36 microM) was lower
				than that of hydroxychloroquine (4.51, 4.06, 17.31, and 12.96
				microM)</FONT></FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>The
				differences in EC50 values were statistically signiﬁcant at a
				MOI of 0.01 (P&lt;0.05) and MOI of 0.2 (P&lt;0.001)</FONT></FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>The
				selectivity index of hydroxychloroquine was lower than
				chloroquine at all MOIs</FONT></FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=3 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Hydroxychloroquine and
			chloroquine were evaluated against SARS-CoV-2 in vitro in African
			green monkey kidney VeroE6 cells</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>Cytotoxicity
				measured by CCK8</FONT></FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>Dose–response
				curves of the two compounds against SARS-CoV-2 were determined at
				four different multiplicities of infection (MOIs) by
				quantiﬁcation of viral RNA copy numbers in the cell supernatant
				at 48h post infection (p.i.).</FONT></FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P> <FONT SIZE=2>Antiviral effect of hydroxychloroquine and
			chloroquine against SARS-CoV-2 infection in vitro </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>African green monkey kidney VeroE6 cells</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>In vivo activity in animal model is an imperfect
			analogue to humans</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.07in; text-indent: 0.07in"><FONT SIZE=2><B>Yao
			X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and
			Projection of Optimized Dosing Design of Hydroxychloroquine for
			the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2
			(SARS-CoV-2). </B></FONT><FONT SIZE=2><I><B>Clin Infect Dis. </B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>What are antiviral and prophylactic profiles of
			hydroxychloroquine and chloroquine in vitro?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro,
			Hydroxychloroquine (EC50=0.72 μM) was more potent than
			chloroquine (EC50=5.47 μM) </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>At
				24 &amp; 48 hours, the EC</FONT></FONT></FONT><FONT COLOR="#000000"><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB></FONT><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>
				values for hydroxychloroquine (24hours, 6.25; 48 hours, 5.85)
				were lower than for chloroquine (24hours, &gt;100; 48 hours,
				18.01)</FONT></FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>PBPK models conducted
			in lung fluid found that hydroxychloroquine was more potent than
			chloroquine</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>Model
				demonstrated that 5 days oral hydroxychloroquine sulfate (loading
				dose of 400 mg twice daily on day 1, followed by 200 mg given
				twice daily for 4 days) may be sufficient for SARS-CoV-2
				infection</FONT></FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P><FONT SIZE=2>Chloroquine and hydroxychloroquine decreased viral
			replication in a concentration-dependent manner</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>Antiviral
				and pharmacological activity was tested using Vero cells infected
				with SARS-CoV-2</FONT></FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>Physiologically-based
				pharmacokinetic models (PBPK) were implemented and drug
				concentrations in lung fluid were simulated under 5 different
				dosing regimens </FONT></FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>Physical,
					chemical, and pharmacokinetic parameters were obtained from the
					literature and published clinical trial data was used to
					validate the models</FONT></FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>In
				vitro antiviral and prophylactic activity of hydroxychloroquine
				and chloroquine </FONT></FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>PBPK
				model for hydroxychloroquine and chloroquine using data from
				literature</FONT></FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>Predict
				drug concentrations under different dosing regimens using the
				PBPK models </FONT></FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Vero cells derived from
			African green monkey kidney</FONT></P>
			<P><BR>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>In vivo activity in animal model is an imperfect
			analogue to humans</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=5 BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Review</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: -0.07in; text-indent: 0.07in; margin-bottom: 0in">
			<FONT SIZE=2><B>Colson P, Rolain JM, Raoult D. Chloroquine for the
			2019 novel coronavirus SARS-CoV-2. </B></FONT>
			</P>
			<P ALIGN=CENTER STYLE="margin-left: -0.07in; text-indent: 0.07in"><FONT SIZE=2><I><B>Int
			J Antimicrob Agents. </B></I></FONT><FONT SIZE=2><B>2020;55(3):105923.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=5 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Commentary on the use of hydroxychloroquine and
			chloroquine in SARS-CoV-2.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Optimal dosage for
			SARS-CoV-2 will need to be assessed in the </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Authors
				comment that based on their experience during the past 5 years in
				patients with long-term treatment (&gt;1 year), </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>a
				hydroxychloroquine dose of 600 mg/day reaches a concentration of
				1 mcg/ml</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Identify that
			hydroxychloroquine would be their first choice in the treatment of
			SARS-CoV-2 </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Purport
				the activity of hydroxychloroquine on viruses is probably the
				same as that of chloroquine since the mechanism is identical and
				suggest hydroxychloroquine would be their first choice for
				SARS-CoV-2</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>For
				optimal treatment it may be necessary to administer a loading
				dose followed by a maintenance dose. </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Review &amp; commentary on the use of
			hydroxychloroquine and chloroquine in SARS-CoV-2, based on their
			experience with 2000 dosages of hydroxychloroquine during the past
			5 years</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>N/A </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% HEIGHT=10 BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>N/A</FONT></P>
			<P><BR>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Study is a review</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Did
				not perform meta-analyses to support arguments</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>

</TABLE>
</details>

<details>
<summary><a name="AzithromycinHydroxychloroquine">Azithromycin + Hydroxychloroquine</a></summary>

<TABLE WIDTH=88% CELLPADDING=7 CELLSPACING=0>
        <COL WIDTH=38*>
        <COL WIDTH=218*>

	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#212f57" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Azithromycin
			+ Hydroxychloroquine</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Mechanism</B></FONT><SUP><FONT SIZE=2>19</FONT></SUP><FONT SIZE=2>:
			In viral respiratory infections, it has been theorized that
			macrolides: 1) downregulate inflammatory response, 2) attenuate
			extreme cytokine production, 3) promote the induction of
			immunoglobulin antibodies</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Experimental
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Gautret P, Lagier JC, Parola P, et
			al. Hydroxychloroquine and azithromycin as a treatment of
			COVID-19: results of an open-label non-randomized clinical trial.
			</B></FONT><FONT SIZE=2><I><B>Int J Antimicrob Agents.
			</B></I></FONT><FONT SIZE=2><B>2020:105949.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Does azithromycin as
			adjuvant to hydroxychloroquine improve viral clearance?</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Study
				evaluated treatment with hydroxychloroquine versus no treatment
				with hydroxychloroquine </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Evaluation
				of hydroxychloroquine + azithromycin combined therapy was not the
				original intent of the study</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>6/6 patients on hydroxychloroquine + azithromycin
			had viral eradication by day 6 compared to 8/14 (57%) on
			hydroxychloroquine and 2/16 (13%) on control</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Non-randomized open-label trial comparing 10 days
			of oral hydroxychloroquine sulfate (200mg, three times a day)
			versus no treatment (non-placebo) in Marseille, France.  </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Virologic clearance at day-6 post-inclusion</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>36 patients with
			SARS-CoV-2 (20 hydroxychloroquine &amp; 16 control)</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>6 of the
				hydroxychloroquine patients received 5 days azithromycin (500mg
				loading dose, then 250mg q24 for 4 days)</FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Azithromycin
					administered based on clinical judgement to prevent bacterial
					super infection </FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Sensitivity
				analysis of hydroxychloroquine/azithromycin: 14
				hydroxychloroquine, 6 hydroxychloroquine/azithromycin, 16 control</FONT></P>
			</UL>
			<P><BR>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Patient Recruitment</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Not
				randomized</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Treatment group:
					only patients at Marseille center</FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Control Group:
					patients who declined hydroxychloroquine at Marseille + patients
					from non-Marseille clinical sites </FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Underpowered based
				on sample size calculations: 24 in each group
				(hydroxychloroquine, control)</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>PCR Sampling of Viral
			Clearance</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patients
				in the control group had higher viral loads at enrollment
				compared to the hydroxychloroquine monotherapy group, which had
				higher viral loads compared to the hydroxychloroquine and
				azithromycin combination group</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Different
				PCR sampling between Marseille (daily) &amp; other centers (every
				other day)</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Analyses</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Survivorship bias:
				6 patients removed from hydroxychloroquine prior to analyses </FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>3 patients
					transferred to ICU while still PCR positive, 1 patient died, 1
					PCR-negative patient left the hospital, 1 withdrew due to nausea
					</FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Confounding by
				indication</FONT></P>
				<UL>
					<LI><P><FONT SIZE=2>Baseline characteristics only presented for
					hydroxychloroquine vs control arm. No subgroup analyses to
					determine if hydroxychloroquine/azithromycin group was different</FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Observational
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><I><B>Gautret P, Lagier JC, Parola P,
			et al. Clinical and microbiological effect of a combination of
			hydroxychloroquine and azithromycin in 80 COVID-19 patients with
			at least a six-day follow up: an observational study. 2020.
			Published online at their organization’s website
			(<A HREF="https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf">https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf</A>);
			not peer-reviewed</B></I></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Describe clinical course, length of
			hospitalization, and change in viral among patients treated
			combined hydroxychloroquine and azithromycin.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Clinical: 15% of
			patients required oxygen therapy</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>3
				patients required transfer to the ICU</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>1
				patient died on the Infectious Disease ward</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Virologic clearance: </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>PCR
				negative (cycle threshold </FONT></FONT><FONT FACE="Symbol, serif"><FONT SIZE=2></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>35):
				83% on day 7, 93% on day 8</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Culture
				negative: 97.5% on day 5</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Length of
			hospitalization: 65/80 (81.3%) were discharged from the hospital
			at the time of writing</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Among
				those discharged: mean total length of stay was 4.6 days (SD, 2.1
				days)</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Mean
					length of stay following treatment initiation was 4.1 days (SD,
					2.2 days)</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Single-arm observational study of patients
			receiving 10 days of oral hydroxychloroquine sulfate (200mg, three
			times) + 5 days azithromycin (500mg loading dose, then 250mg q24
			for 4 days)</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Three primary
			endpoints:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Aggressive
				clinical course: defined as requiring oxygen therapy or transfer
				to the ICU after </FONT></FONT><FONT FACE="Symbol, serif"><FONT SIZE=2></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>
				three days of treatment, </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Contagiousness:
				defined as assessed by viral PCR cycle threshold </FONT></FONT><FONT FACE="Symbol, serif"><FONT SIZE=2></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>35
				and negative culture</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Length
				of hospitalization, among patients discharged at time of writing</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>80 patients with
			PCR-documented SARS-CoV-2 via nasopharyngeal swab admitted to ID
			unit</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Included the 6
				patients treated with hydroxychloroquine + azithromycin in the
				first study</FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Inclusion
				criteria:  </FONT></FONT><FONT FACE="Symbol, serif"><FONT SIZE=2></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>3
				days combination therapy and </FONT></FONT><FONT FACE="Symbol, serif"><FONT SIZE=2></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>6
				days follow-up</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Exclusion
				criteria: Patients with contraindication to either therapy, QTc
				&gt;500, ECG suggestive of channelopathy, or other abnormalities
				on ECG which increased the risk</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>National early warning
			score (NEWS) on admission (75/80 participants):</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Low (NEWS 0-4): 69
				(92%)</FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Medium (NEWS 5-6):
				4 (5.3%)</FONT></P>
				<LI><P><FONT SIZE=2>High (NEWS </FONT><FONT FACE="Symbol, serif"><FONT SIZE=2></FONT></FONT><FONT SIZE=2>7)
				</FONT><FONT FACE="Wingdings, serif"><FONT SIZE=2></FONT></FONT><FONT SIZE=2>
				2 (2.7%)</FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Design</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Single-arm
				study is difficult to interpret in emerging diseases for which
				the natural history is not well understood</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Single-arm
				trials cannot establish efficacy of a therapy   </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Participants</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Wide
				range of time between symptom onset and treatment initiation:
				Mean time 4.9 days (SD, 3.6 days), Range, 1-17 days</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Majority
				of patients (92%) had low NEWS score</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Analyses</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Criteria
				for discharge changed during the study period</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Length
				of stay cannot adequately be defined, as 14 patients were still
				hospitalized at the time of writing</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Variable
				length of follow-up between patients</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Interpretation of
			results</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Confounding:
				18 patients (22.5%) received additional antibiotics (ceftriaxone)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Nasopharyngeal
				samples not consistently collected and cultures not performed for
				all patients (number of patients not reported)</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Difficult
					to interpret change in viral load over time</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Descriptive
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: 0.18in; margin-right: 0.18in"><FONT SIZE=2><B>Molina
			JM, Delaugerre C, Goff JL, et al. No Evidence of Rapid Antiviral
			Clearance or Clinical Benefit with the Combination of
			Hydroxychloroquine and Azithromycin in Patients with Severe
			COVID-19 Infection. </B></FONT><FONT SIZE=2><I><B>Médecine et
			Maladies Infectieuses. </B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>What are the virologic &amp; clinical outcomes in
			patients hospitalized with COVID-19?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>No evidence of clinical
			benefit associated with combined hydroxychloroquine + azithromycin
			among 11 hospitalized patients with severe COVID-19 </FONT>
			</P>
			<OL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>8/10
				(80%; 95% CI: 49-94%) of living patients were still positive by
				PCR at days 5 &amp; 6 following treatment</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Adverse
				effects were noted in 4 patients within 5 days: 1 patient died, 2
				patients were transferred to the ICU, therapy was discontinued in
				1 patient due to QT-prolongation (day 4)</FONT></FONT></FONT></FONT></FONT></P>
			</OL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Prospective case report among 11 hospitalized
			patients in Paris, France receiving 10 days of oral
			hydroxychloroquine sulfate (200mg, three times) + 5 days
			azithromycin (500mg loading dose, then 250mg q24 for 4 days)</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Viral carriage at day 6</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>11 consecutive
			hospitalized patients in Paris, France</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>8
				had significant comorbidities, including cancer (solid, 3
				patients; hematological, 2 patients) &amp; HIV-infection (1
				patient)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>At
				the time of initiation, 10/11 had a fever and received nasal
				oxygen therapy </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>Case
				series</FONT></FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>Brief
				report: No supplemental data</FONT></FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Evidence in
			SARS-CoV-1 &amp; MERS-CoV&nbsp;</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: 0.18in; margin-right: 0.18in; margin-bottom: 0in">
			<FONT SIZE=2><B>Arabi YM, Deeb AM, Al-Hameed F, et al. Macrolides
			in critically ill patients with Middle East Respiratory Syndrome. </B></FONT>
			</P>
			<P ALIGN=CENTER STYLE="margin-left: 0.18in; margin-right: 0.18in"><FONT SIZE=2><I><B>Int
			J Infect Dis. </B></I></FONT><FONT SIZE=2><B>2019;81:184-190.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does macrolide therapy reduce mortality in
			patients with MERS-CoV?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<OL START=3>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				association between macrolide therapy and 90-day mortality </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				difference in MERS-CoV clearance</FONT></FONT></FONT></FONT></FONT></P>
			</OL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Multicenter retrospective cohort study comparing
			macrolide therapy to no treatment across 14 hospitals in Saudi
			Arabia</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2><U>Primary
				outcome</U></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>:
				90-day all-cause mortality</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2><U>Secondary
				outcome</U></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>:
				time to clearance of MERS-CoV </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Defined
					as the time from ICU admission until the PCR was negative on two
					occasions, without a positive test afterward</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Sensitivity
				Analyses: Excluded patients receiving macrolide after 3</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2>rd</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2>
				ICU day</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>349 critically ill
			patients with MERS-CoV (136 macrolide therapy &amp; 213 control)</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Macrolide
				treatment group: received azithromycin, clarithromycin or
				erythromycin within three days prior to admission to ICU, or at
				any time during their stay in ICU, up to 28 days </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Control
				group: patients not given macrolides during the same timeframe</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Confounding by
			indication</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patients
				on macrolide therapy had significantly longer ICU and hospital
				length of stay, as well as days on ventilator</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Duration
				of macrolide therapy unclear</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>

</TABLE>
</details>

<details>
<summary><a name="Remdesivir">Remdesivir</a></summary>

<TABLE WIDTH=88% CELLPADDING=7 CELLSPACING=0>
        <COL WIDTH=38*>
        <COL WIDTH=218*>

	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#212f57" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="text-indent: -0.01in"><FONT COLOR="#ffffff"><FONT SIZE=2><B>Remdesivir</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2><B>Mechanism:
			</B></FONT><FONT SIZE=2>Broad-spectrum nucleotide analog.
			Remdesivir is a monophosphoramidate pro-drug, which is metabolized
			into an analog of adenosine-triphosphate (ATP). Incorporation into
			nascent viral RNA causes pre-mature termination of viral RNA
			transcription, resulting in decreased viral RNA production.</FONT><SUP><FONT SIZE=2>5,48</FONT></SUP><FONT SIZE=2>
			</FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>SARS-CoV
				and SARS-CoV-2 share 82% of their RNA sequence identity</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Share
					96% of RNA-dependent RNA polymerase (RdRp) sequence identity</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2>49</FONT></FONT></SUP></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Descriptive
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-bottom: 0in"><FONT SIZE=2><B>Holshue
			ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel
			Coronavirus in the United States. </B></FONT>
			</P>
			<P ALIGN=CENTER><FONT SIZE=2><I><B>New England Journal of
			Medicine. </B></I></FONT><FONT SIZE=2><B>2020;382(10):929-936.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>To describes the clinical features of the first
			case of SARS-CoV-2 infection confirmed in the United States</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patient
				clinically improved, beginning on hospital day 8 (illness day 12)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				adverse events associated with the infusion of Remdesivir were
				observed</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT FACE="Times New Roman, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Case
			report of the inpatient clinical course of the first patient with
			confirmed SARS-CoV-2 in Snohomish County, Washington.</FONT></FONT></FONT></FONT></P>
			<P><FONT FACE="Times New Roman, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patient
			treated with IV Remdesivir for compassionate use on Hospital Day
			7, due to worsening clinical status.</FONT></FONT></FONT></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Clinical course &amp; improvement</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>35-year-old male with a past medical history of
			</FONT><FONT COLOR="#00000a"><FONT SIZE=2>hypertriglyceridemia and
			recent travel to Wuhan, China, who presented with 4 days of </FONT></FONT><FONT SIZE=2>mild
			cough and low-grade fevers, and subsequently developed pneumonia
			(illness day 9) and hypoxemia, and was treated with nasal cannula
			oxygen supplementation, IV vancomycin and cefepime, and
			compassionate use Remdesivir.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Impact of Remdesivir on clinical improvement is
			unclear</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>In Vitro </B></FONT></FONT>
			</P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-bottom: 0in"><FONT SIZE=2><B>Wang M,
			Cao R, Zhang L, et al. Remdesivir and chloroquine effectively
			inhibit the recently emerged novel coronavirus (2019-nCoV) in
			vitro. </B></FONT>
			</P>
			<P ALIGN=CENTER><FONT SIZE=2><I><B>Cell Res. </B></I></FONT><FONT SIZE=2><B>2020;30(3):269-271.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does Remdesivir (GS- 5734) have in vitro antiviral
			efficacy against a clinical isolate of SARS-CoV-2? </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Demonstration of
			efficacy of Remdesivir in vitro against SARS-CoV-2</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>In
				vitro activity of Remdesivir against 2019-nCoV in monkey kidney
				cells at low- micromolar concentrations (half-maximal effective
				concentration [EC</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>],
				0.77 μM; EC90, 1.76 μM;), high  cytotoxicity (cytotoxic
				concentration [CC</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>],&gt;100),
				and high selectivity (selectivity  index [SI], &gt;129.87)
				suggesting effective concentration likely to be achieved in
				non-human primates</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Preliminary
				data of inhibition of virus infection in human liver cells  </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Time-of-
				addition assay showed Remdesivir functioned at a stage post virus
				entry </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro study
			evaluating Vero E6 cells (ATCC-1586) infected with 2019-nCoV
			(clinical isolate nCoV-2019BetaCoV/Wuhan/WIV04/2019) </FONT>
			</P>
			<P><FONT SIZE=2>at a MOI of 0.05 and then treated with different
			doses of antiviral</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro antiviral
			efficacy:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Mean
				inhibition of virus yield (quantified by qRT-PCR) and
				cytotoxicity (CCK-8 assay)</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P><FONT SIZE=2>Determination of when Remdesivir acts, relative to
			viral entry, using a time-of-addition assay</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro cell lines:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>African
				green monkey kidney Vero E6 cell line </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Human
				liver cancer Huh7 cell line </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Difficult to extrapolate in vivo activity and
			dosing from in vitro experiments</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Evidence in
			SARS-CoV-1 &amp; MERS-CoV&nbsp;</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>de Wit E, Feldmann F, Cronin J, et
			al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in
			the rhesus macaque model of MERS-CoV infection. </B></FONT><FONT SIZE=2><I><B>Proc
			Natl Acad Sci U S A. </B></I></FONT><FONT SIZE=2><B>2020;117(12):6771-6776.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does Remdesivir have antiviral efficacy against
			MERS-CoV in a rhesus macaque model? </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Efficacy demonstrated
			in pre-exposure and post-exposure treatment groups</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Prophylactic
				Remdesivir administered 24 hours prior to infection: Completely
				prevented clinical disease, strongly reduced viral replication in
				respiratory tissue, and prevented lung lesions </FONT>
				</P>
				<LI><P><FONT SIZE=2>Therapeutic Remdesivir administered 12 hours
				post-infection: Reduced clinical signs of infection, reduced
				virus replication in lungs and decreased presence and severity of
				lung lesions </FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo animal model
			among 18 rhesus macaques randomly assigned to three groups of six
			animals. In each arm, half were treated 24 hours before MERS-CoV
			inoculation and the other half were treated at 12 hours after
			MERS-CoV inoculation.</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Control
				group (6): 1 mL/kg vehicle solution </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				group (12): 5 mg/kg Remdesivir</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Clinical
				signs of disease</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Viral
				replication</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Lung
				imaging and histopathology</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>18 rhesus macaques</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Difficult to
			extrapolate in vivo activity and dosing from in vitro experiments</FONT></P>
			<P><FONT SIZE=2>In vivo activity in animal model is an imperfect
			analogue to humans</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-bottom: 0in"><FONT SIZE=2><B>Sheahan
			TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734
			inhibits both epidemic and zoonotic coronaviruses. </B></FONT>
			</P>
			<P ALIGN=CENTER><FONT SIZE=2><I><B>Sci Transl Med. </B></I></FONT><FONT SIZE=2><B>2017;9(396).</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does Remdesivir (GS- 5734) have in vitro and in
			vivo antiviral efficacy against SARS-CoV and MERS-CoV?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Antiviral efficacy
				in Human airway epithelial (HAE) cells against both SARS and
				MERS-CoV with low IC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>
				(0.069 µM; SARS-CoV and 0.074 µM; MERS-CoV)</FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Efficacy at
					concentrations that are at least 100-fold lower than those with
					observable cytotoxicity</FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Broad-spectrum
				activity against a diverse array of human and zoonotic CoV</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Prophylaxis in
				SARS-CoV: Reduced viral lung titers, ameliorated symptoms,
				decreased lung pathology (intra-alveolar edema, denuding
				bronchiolitis etc), and prevented defects in pulmonary function  </FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Post-infectious
				administration in SARS-CoV relative to peak viral replication and
				lung damage:</FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Early
					administration (1-day post-infection): Significantly suppressed
					virus lung titers and improved pulmonary function</FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Late
					administration (2-days post-infection): no difference in disease
					severity or survival </FONT>
					</P>
					<UL>
						<LI><P><FONT SIZE=2>Significant reduction in viral load </FONT>
						</P>
					</UL>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a">&nbsp;<FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Multiple
				in vitro models to measure the antiviral effect and cytotoxicity
				of GS-5734, compared to vehicle, on multiple CoV strains</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Blinded
				and randomized antiviral efficacy study within mouse models of
				severe CoV disease</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro antiviral
			efficacy:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Inhibition of
				viral replication: half-maximum effective concentration,
				cytotoxicity</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo antiviral
			efficacy:</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Weight
				loss, survival, viral titers, pulmonary pathology, American
				Thoracic Society lung injury score</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro: human lung
			epithelial cell line (Calu-3 2B4 [2B4]), human airway epithelial
			(HAE) cell cultures</FONT></P>
			<P><FONT SIZE=2>In-vivo: </FONT><FONT SIZE=2><I>Ces1c</I></FONT><SUP><FONT SIZE=2>−/−</FONT></SUP><FONT SIZE=2>&nbsp;mouse
			model; three male marmosets</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Difficult to
			extrapolate in vivo activity and dosing from in vitro experiments</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo activity in
			animal model is an imperfect analogue to humans</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Window
				for therapeutic administration after the onset of symptoms but
				prior to the peak of virus replication differs between humans and
				mouse model</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Sheahan TP, Sims AC, Leist SR, et
			al. Comparative therapeutic efficacy of remdesivir and combination
			lopinavir, ritonavir, and interferon beta against MERS-CoV. </B></FONT><FONT SIZE=2><I><B>Nat
			Commun. </B></I></FONT><FONT SIZE=2><B>2020;11(1):222.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does Remdesivir (GS- 5734), in comparison to
			combination lopinavir, ritonavir and interferon beta, have
			comparable in vitro and in vivo antiviral efficacy against
			MERS-CoV? </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>When compared with
			combination lopinavir, ritonavir and interferon beta, Remdesivir
			demonstrated superior antiviral activity against MERS-CoV in vitro
			and in vivo.</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Potent inhibition
				of MERS-CoV replication with an EC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>&nbsp;of
				0.09 µM, no observable cytotoxicity up to 10μM, and a
				selectivity index &gt; 100</FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Superior in vitro
				antiviral activity compared with Lopinavir and Ritonavir</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Significant
				decrease in weight loss, plaque forming units</FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Pre-exposure
				prophylaxis: significantly reduced mortality, lung hemorrhage,
				and viral lung titers</FONT></P>
				<UL>
					<LI><P><FONT SIZE=2>Significantly reduced lung injury scores</FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Parallel
				antiviral assays assessing antiviral efficacy and cytotoxicity in
				the Calu-3 human lung cell line&nbsp;</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Efficacy
				of prophylactic Remdesivir, compared to vehicle and combination
				therapy, in a new transgenic mouse model of MERS-CoV pathogenesis</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Single
				therapeutic efficacy study with a lethal dose of MERS-CoV</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro antiviral
			efficacy:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Inhibition of
				viral replication: half-maximum effective concentration,
				cytotoxicity</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo antiviral
			efficacy:</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Weight
				loss, survival, viral titers, pulmonary pathology, American
				Thoracic Society lung injury score</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro: Calu-3 cell
			line</FONT></P>
			<P><FONT SIZE=2>In-vivo: </FONT><FONT SIZE=2><I>Ces1c</I></FONT><SUP><FONT SIZE=2>−/−</FONT></SUP><FONT SIZE=2>&nbsp;</FONT><FONT SIZE=2><I>hDPP4</I></FONT><FONT SIZE=2>&nbsp;mouse
			model</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Difficult to
			extrapolate in vivo activity and dosing from in vitro experiments</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo activity in
			animal model is an imperfect analogue to humans</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Window
				for therapeutic administration after the onset of symptoms but
				prior to the peak of virus replication differs between humans and
				mouse model </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Evidence in
			Ebola</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-bottom: 0in"><FONT SIZE=2><B>Mulangu
			S, Dodd LE, Davey RT, et al. A Randomized, Controlled Trial of
			Ebola Virus Disease Therapeutics. </B></FONT>
			</P>
			<P ALIGN=CENTER><FONT SIZE=2><I><B>New England Journal of
			Medicine. </B></I></FONT><FONT SIZE=2><B>2019;381(24):2293-2303.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Evaluation of the safety and efficacy of four
			investigational therapies during an Ebola virus outbreak in the
			Democratic Republic of Congo.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
				<FONT COLOR="#000000"><FONT SIZE=2>Study stopped after interim
				analysis showed mortality benefit of REGN-EB2 (33% died) and
				mAb114 (35% died) </FONT></FONT>
				</P>
				<UL>
					<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
					<FONT COLOR="#000000"><FONT SIZE=2>Remdesivir: 53% died</FONT></FONT></P>
					<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
					<FONT COLOR="#000000"><FONT SIZE=2>ZMapp:49.7% died </FONT></FONT>
					</P>
				</UL>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
				<FONT COLOR="#000000"><FONT SIZE=2>During Remdesivir loading
				dose, one patient experienced hypotension, followed rapidly by
				cardiac arrest </FONT></FONT>
				</P>
				<UL>
					<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in"><FONT COLOR="#000000"><FONT SIZE=2>Death
					could not be distinguished from underlying fulminant Ebola virus
					disease</FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Randomized control
			trial of investigational therapies among patients who had a
			positive result for Ebola virus RNA on
			reverse-transcriptase–polymerase-chain-reaction assay in the
			Democratic Republic of Congo.</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>1:1:1:1
				ratio to intravenous therapy </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Control
					(triple monoclonal antibody ZMapp): 50mg/kg every third day, for
					a total of three doses</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Remdesivir:
					loading dose of 200 mg in adults (adjusted for body weight in
					pediatric patients), followed by a daily maintenance dose (100
					mg in adults), and continuing for 9 to 13 days, depending on
					viral load </FONT></FONT></FONT></FONT></FONT>
					</P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Single
					monoclonal antibody MAb114: single infusion, 50 mg/kg </FONT></FONT></FONT></FONT></FONT>
					</P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Triple
					monoclonal antibody REGN-EB3: single infusion, 150 mg/kg</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Originally
				designed as a three-group trial</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Protocol
					was up-dated in January 2019 to add REGN-EB3 as a fourth group </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Randomization
				was stratified according to baseline nucleoprotein
				cycle-threshold (Ct) value (≤22.0 or &gt;22.0) </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Death at 28 days</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>681 patients of all
			ages with positive Ebola RNA on PCR in the Democratic Republic of
			Congo between November 20, 2018 and August 9, 2019.</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Inclusion:
				Positive result on RT-PCR within 3 days before screening </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>All
					ages and pregnant women were included</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Neonates
					&lt;7 days of age were eligible if the mother had documented
					Ebola virus </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exclusion:
				Receipt of another investigational agent within 30 days</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Noted delays from
				randomization to starting ZMapp or Remdesivir</FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Higher creatinine
				and aminotransferases in ZMapp and Remdesivir groups suggests the
				patients randomized to these two groups may have been sicker </FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>High percentage of
				missing baseline data</FONT></P>
				<LI><P><FONT SIZE=2>Multiple logistical and supply-chain
				challenges</FONT></P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-bottom: 0in"><FONT SIZE=2><B>Warren
			TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small
			molecule GS-5734 against Ebola virus in rhesus monkeys. </B></FONT>
			</P>
			<P ALIGN=CENTER><FONT SIZE=2><I><B>Nature. </B></I></FONT><FONT SIZE=2><B>2016;531(7594):381-385.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Report of the discovery of a novel small molecule
			GS-5734 (Remdesivir) with antiviral post-exposure activity against
			Ebola virus.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=JUSTIFY STYLE="margin-left: 0.25in; margin-right: 0.17in; text-indent: -0.25in; margin-bottom: 0in">
			<FONT COLOR="#000000"><FONT SIZE=2>In vitro:</FONT></FONT></P>
			<UL>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
				<FONT COLOR="#000000"><FONT SIZE=2>Inhibition of replication of
				Ebola virus across multiple human cell types, including
				macrophages and endothelial cells</FONT></FONT></P>
				<UL>
					<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
					<FONT COLOR="#000000"><FONT SIZE=2>Half-maximum effective
					concentration (EC<SUB>50</SUB>): 0.06 to 0.14 μM&nbsp;</FONT></FONT></P>
					<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
					<FONT COLOR="#000000"><FONT SIZE=2>Low cytotoxicity (CC<SUB>50</SUB>)
					&gt;20 μM</FONT></FONT></P>
					<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
					<FONT COLOR="#000000"><FONT SIZE=2>Dose-dependent reductions in
					viral RNA production and infectious virus yield</FONT></FONT></P>
				</UL>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
				<FONT COLOR="#000000"><FONT SIZE=2>Broad-spectrum inhibition of
				replication in RNA viral pathogens, including respiratory
				syncytial virus (RSV), Junín virus, Lassa fever virus, and
				Middle East respiratory syndrome virus</FONT></FONT></P>
				<UL>
					<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
					<FONT COLOR="#000000"> <FONT SIZE=2>Inactive against
					alphaviruses or retroviruses</FONT></FONT></P>
				</UL>
			</UL>
			<P ALIGN=JUSTIFY STYLE="margin-left: 0.25in; margin-right: 0.17in; text-indent: -0.25in; margin-bottom: 0in">
			<FONT COLOR="#000000"><FONT SIZE=2>In vivo:</FONT></FONT></P>
			<UL>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
				<FONT COLOR="#000000"><FONT SIZE=2>Dose-dependent survival
				benefit</FONT></FONT></P>
				<UL>
					<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
					<FONT COLOR="#000000"><FONT SIZE=2>100% survival at 10mg/kg
					daily for 12 days</FONT></FONT></P>
				</UL>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
				<FONT COLOR="#000000"><FONT SIZE=2>Significant reduction in viral
				RNA</FONT></FONT></P>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in"><FONT COLOR="#000000"><FONT SIZE=2>Active
				form identified in peripheral blood mononuclear cells for <FONT FACE="Symbol, serif"></FONT>24h
				following 10mg/kg IV dose</FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro study among
			multiple cell lines infected with RNA viruses, including Ebola
			Virus.</FONT></P>
			<P><FONT SIZE=2>In vivo study of Ebola-infected rhesus monkeys.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro antiviral
			efficacy:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Half-life,
				half-maximum effective concentration, cytotoxicity, change in
				viral RNA production</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo antiviral
			efficacy:</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Survival,
				change in viral RNA production</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro cell lines:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>HEp-2
				(CCL-23), PC-3 (CCL-1435), HeLa (CCL-2), U2OS (HTB-96), Vero
				(CCL-81), HFF-1 (SCRC-1041), HepG2 (HB-8065), MT-4, Huh-7&nbsp;</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Primary
				human hepatocytes, immortalized human microvascular endothelial
				cells (HMVEC-TERT), human peripheral blood mononuclear cells</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P><FONT SIZE=2>In vivo: rhesus monkeys infected with Ebola virus</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Difficult to
			extrapolate in vivo activity and dosing from in vitro experiments</FONT></P>
			<P><FONT SIZE=2>In vivo activity in non-human primates is an
			imperfect analogue to humans</FONT></P>
		</TD>
	</TR>

</TABLE>
</details>

<details>
<summary><a name="Ribavirin">Ribavirin</a></summary>

<TABLE WIDTH=88% CELLPADDING=7 CELLSPACING=0>
        <COL WIDTH=38*>
        <COL WIDTH=218*>

	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#212f57" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Ribavirin</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT COLOR="#00000a"><FONT SIZE=2><B>Mechanism: </B></FONT></FONT><FONT COLOR="#00000a"><FONT SIZE=2>Guanosine
			analog that inhibits RNA synthesis, via viral RdRp, as well as
			inhibits mRNA capping</FONT></FONT><FONT COLOR="#00000a"><SUP><FONT SIZE=2>50</FONT></SUP></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Evidence in
			SARS-CoV-1 &amp; MERS-CoV&nbsp;</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Al-Tawfiq JA, Momattin H, Dib J,
			Memish ZA. Ribavirin and interferon therapy in patients infected
			with the Middle East respiratory syndrome coronavirus: an
			observational study. </B></FONT><FONT SIZE=2><I><B>Int J Infect
			Dis. </B></I></FONT><FONT SIZE=2><B>2014;20:42-46.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>What outcomes are associated with the use of
			combination of interferon-a2b and ribavirin in the management of
			MERS-CoV infections?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>5/5 (100%) of patients
			died of their illness</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>None
				of the patients responded to the supportive or therapeutic
				interventions </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Adverse effects from
			combination ribavirin and interferon therapy were observed in
			three cases </FONT>
			</P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Pancreatic
				enzyme elevation (2 patients), thrombocytopenia (1 patient), and
				significant hemolysis (1 patient)</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective case
			series of five MERS-CoV- positive patients who received a
			combination therapy of interferon-a2b and ribavirin </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Initial
				phase of the Al-Hasa outbreak (April - May 2013) </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Received
				subcutaneous interferon-a2b 100 mg once per week + oral ribavirin
				2g loading dose followed by 400-800mg ever 8 hours</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Also
				treated with oseltamivir, antibiotics (levofloxacin, imipenem),
				and corticosteroids</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Description of therapeutic schedule, clinical
			course, clinical and laboratory parameters, and outcomes </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>5 critically ill
			patients with acute respiratory distress syndrome requiring
			mechanical ventilation</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>All
				patients had multiple severe comorbidities (e.g. diabetes,
				hypertension, chronic renal disease) </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Patients treated late
			in disease course</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Due
				to unknown epidemiology and clinical characteristics, there was a
				median of 19 (range 10–22) days between admission and
				initiation of therapy</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Did not collect serial
			MERS-CoV viral loads and therefore unable to assess virologic
			response</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Confounding: patients
			had abnormal laboratory findings before the initiation of
			combination therapy,</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Therefore,
				cannot determine if adverse events were due solely to
				therapeutics versus disease progression</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Arabi YM, Shalhoub S, Mandourah Y,
			et al. Ribavirin and Interferon Therapy for Critically Ill
			Patients With Middle East Respiratory Syndrome: A Multicenter
			Observational Study. </B></FONT><FONT SIZE=2><I><B>Clin Infect
			Dis. </B></I></FONT><FONT SIZE=2><B>2019.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Is ribavirin RBV + recombinant interferon (rIFN)
			associated with decreased 90-day mortality and increased viral
			clearance among patients with MERS-CoV?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>No reduction in 90-day
			mortality </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Crude
				90-day mortality was higher in those receiving RBV + IFN versus
				those without (74% vs 62%, p=0.02),</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>increased
				adjusted mortality in patients receiving RBV + rIFN therapy:
				adjusted odds ratio (OR) 2.27 (95% CI, 1.20–4.32; </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2><I>P
				</I></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>= 0.01).
				</FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>increased
				mortality in Cox proportional hazards analysis accounting for
				time-varying exposure: HR 1.52 (95% CI, 1.13–2.06; </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2><I>P
				</I></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>= 0.006)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				significant difference in marginal structural model: OR 1.03 (95%
				CI, 0.73–1.44]; </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2><I>P
				</I></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>= 0.87) </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in"><FONT COLOR="#000000"><FONT SIZE=2>No
			difference in rate of MERS-CoV RNA clearance</FONT></FONT></P>
			<UL>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
				<FONT COLOR="#000000"><FONT SIZE=2>adjusted HR 0.65 (95% CI,
				.30–1.44; <I>P </I>= 0.29)</FONT></FONT></P>
			</UL>
			<P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in"><FONT COLOR="#000000"><FONT SIZE=2>Secondary
			analyses</FONT></FONT></P>
			<UL>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
				<FONT COLOR="#000000"><FONT SIZE=2>Increased length of ICU stay
				among RBV + rINF group (P=0.02) </FONT></FONT>
				</P>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
				<FONT COLOR="#000000"><FONT SIZE=2>No difference in length of
				hospitalization (P=0.48)</FONT></FONT></P>
				<LI><P ALIGN=JUSTIFY STYLE="margin-right: 0.17in; margin-bottom: 0in">
				<FONT COLOR="#000000"><FONT SIZE=2>Increased in-hospital
				mortality among RBV + rINF group (P=0.03)</FONT></FONT></P>
			</UL>
			<P ALIGN=JUSTIFY STYLE="margin-right: 0.17in"><FONT COLOR="#000000"><FONT SIZE=2>Safety:
			Patients receiving RBV + IFN required more blood transfusions
			compared to those who did not receive treatment (40% vs 28%,
			p=0.02)</FONT></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective
			multicenter observational study across 14 hospitals in 5 cities in
			Saudi Arabia between September 2012 and January 2018</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>144
				critically ill patients with laboratory-confirmed MERS who
				received RBV 2g PO load followed by 600-1200mg q8h + IFN (a2a,
				a2b, b1a) versus 205 controls</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exposure:
					RBV + rIFN therapy, defined as RBV/rIFN combination, RBV alone,
					or rIFN alone</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Comparator
					group: no RBV or rIFN </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Therapy
				initiation (median [IQR]): 2 days (IQR, 1-3 days) from ICU
				admission</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>9.0
					days (IQR, 6-12 days) from symptom onset </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>60%
				of patients receiving RBV + rINF also received corticosteroids</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Primary outcomes:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>90-day
				mortality and MERS </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Coronavirus
				(MERS-CoV) RNA clearance, defined as time from ICU admission
				until 2 negative tests without a subsequent positive test </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Secondary outcomes:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>ICU
				and hospital mortality </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>ICU
				and hospital length of stay </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P><FONT SIZE=2>Safety endpoints</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>All critically ill
			patients (349) with MERS admitted to the intensive care units
			(ICUs) between September 2012 and January 2018 </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>144
				(41%) patients received ribavirin + rIFN therapy </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exclusion:
				enrollment in MERS-CoV Infection Treated with a Combination of
				Lopinavir/Ritonavir and Interferon β-1b (MIRACLE) trial </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Imbalance
				in baseline characteristics between groups</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Quantitative
				viral loads were not available</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Sufficient
					data to assess MERS-CoV RNA clearance were available for only
					about 50% of the patients </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Practices
				for repeating MERS-CoV rRT-PCR varied among centers </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-bottom: 0in"><FONT SIZE=2><B>Chu CM,
			Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the
			treatment of SARS: initial virological and clinical findings. </B></FONT>
			</P>
			<P ALIGN=CENTER><FONT SIZE=2><I><B>Thorax. </B></I></FONT><FONT SIZE=2><B>2004;59(3):252-256.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Do patients with SARS have improved clinical and
			virologic response when treated with combination
			lopinavir/ritonavir + ribavirin (RBV) versus ribavirin
			monotherapy?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Patients treated with
			combination lopinavir/ritonavir + RBV had improved clinical and
			virologic response, compared to RBV controls</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Milder
				disease course (diarrhea, recurrence of fever, and chest
				radiographs)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Progressive
				decrease in viral load</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Significantly
				lower rates of ARDS &amp; mortality at 21 days (2.4% v 28.8%,
				p=0.001)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"> <FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Fewer
				nosocomial infections </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Mild adverse events in
			treatment arm (n=11): GI upset, liver dysfunction, headache &amp;
			blurred vision </FONT>
			</P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Hgb
				dropped </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2><U>&gt;</U></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>
				2g/dL in 29 patients receiving LPV/r + RBV</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Open trial of a
			combination of a lopinavir/ritonavir versus control between 24
			March and 28 April 2003</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>All
				patients received 14 days of RBV: 4g oral loading dose, followed
				by 1.2 g every 8 hours</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>If
					patient could not tolerate oral RBV, received IV 8mg/kg every 8
					hours</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"> <FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>All
				patients received a reducing regimen of corticosteroid for 21
				days</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Starting
					dose: hydrocortisone 100–200 mg every 6–8 hours or
					methylprednisolone 3 mg/kg/day</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patients
					who developed dyspnea or hypoxia received pulses of intravenous
					methylprednisolone (0.5–1 g/day up to 4 g) </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				group additionally received a combination of oral lopinavir (400
				mg)/ritonavir (100 mg) every 12 hours for 14 days </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Initial
					treatment subgroup (n = 12): lopinavir/ritonavir started before
					pulse methylprednisolone </FONT></FONT></FONT></FONT></FONT>
					</P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Rescue
					treatment subgroup (n = 29): lopinavir/ritonavir started after
					pulse methylprednisolone </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>152
				patients</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Historical
					controls (n=111): Patients treated before April 16, 2003</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
					group (n=41): Patients presenting after April 16, 2003</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Serial
				quantitative RT-PCR performed on days 5, 10, 15, and 20 after
				onset of symptoms </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Follow-up:
				3 weeks were treated with a combination of lopinavir/ritonavir
				and ribavirin</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Clinical progress &amp; virologic outcomes</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>152 consecutive
			patients with probable SARS </FONT>
			</P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exclusion
				criteria: development of ARDS</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Not randomized</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Imbalance
				in baseline characteristics between groups</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P><FONT SIZE=2>Unmeasured confounders</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Omrani AS, Saad MM, Baig K, et al.
			Ribavirin and interferon alfa-2a for severe Middle East
			respiratory syndrome coronavirus infection: a retrospective cohort
			study. </B></FONT><FONT SIZE=2><I><B>Lancet Infect Dis.
			</B></I></FONT><FONT SIZE=2><B>2014;14(11):1090-1095.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Is combination ribavirin (RBV) and interferon
			alfa-2a (IFN), compared to supportive treatment only, associated
			with improved mortality among patients with severe MERS-CoV
			infection?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Mortality:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Significantly
				lower rates of mortality in treatment group by day 14 (70% vs
				29%, p=0.004)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				difference at 28 days (30% vs 17%, p=0.054)</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Significantly lower
			baseline absolute neutrophil count in the comparator group (2.99
			vs 4.42, p=0.017)</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Adverse events:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Significantly
				greater reduction in hemoglobin in treatment arm (mean 4.32g/dL
				vs 2.14g/dL, p=0.002)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				premature discontinuation secondary to adverse effects</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective cohort
			study of 44 patients with MERS-CoV infection and pneumonia
			requiring ventilation support in Saudi Arabia between Oct 23, 2012
			and May 1, 2014 </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				group (n=20): subcutaneous IFN-a2a administered weekly + oral RBV
				2g loading dose, followed by 600-1200mg every 8 hours</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Initiated
					therapy at a median of 3 days [range 0–8] after diagnosis</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Comparator
				group (n=24): supportive therapy</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Survival at 14 &amp; 28 days </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>20 patients with
			laboratory-confirmed MERS-CoV infection between Oct 23, 2012 and
			May 1, 2014</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>All patients were
			critically ill with comorbidities</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Inclusion
				criteria: age ≥ 16 years with severe pneumonia requiring
				invasive or non-invasive ventilation </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exclusion
				criteria: no ventilator support, end stage renal disease</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective,
			non-randomized study </FONT>
			</P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Selection bias</FONT></P>
			<P><FONT SIZE=2>Unmeasured confounders </FONT>
			</P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Shalhoub S, Farahat F, Al-Jiffri
			A, et al. IFN-alpha2a or IFN-beta1a in combination with ribavirin
			to treat Middle East respiratory syndrome coronavirus pneumonia: a
			retrospective study. </B></FONT><FONT SIZE=2><I><B>J Antimicrob
			Chemother. </B></I></FONT><FONT SIZE=2><B>2015;70(7):2129-2132.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Are interferon (IFN) + ribavirin efficacious in
			reducing MERS-CoV-related mortality rates?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Overall mortality rate
			was 69% (22/32)</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>9/10
				(90%) patients with positive plasma MERS-CoV PCR died, compared
				with 4/9 (44%) with negative plasma MERS-CoV PCR</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Higher
				mortality in interferon α group (11/13, 85%) compare to
				interferon β group (7/11, 64%)</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Not
					significantly different (P=0.24) </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>2/4
				(50%) patients switched from interferon α to interferon β died</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>1/3
				(33%) patients who did not receive any interferon therapy
				survived</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>100%
				mortality inpatients patients with renal failure</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Age
					&gt; 50 years (P=0.001) and diabetes mellitus (P=0.004) noted to
					be at higher risk for mortality</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
			<P><FONT SIZE=2>Median duration of viral shedding in recovered
			patients was 11 days (range 6–38 days)</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Sequential
			retrospective cohort study among hospitalized patients with
			MERS-CoV pneumonia in Saudi Arabia, between April 1, 2014 and June
			30, 2014 </FONT>
			</P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Treatment protocols
			(n=32): </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Interferon
				α (n=13): Subcutaneous IFN-a2a (180 mg) administered once weekly
				+ oral ribavirin (loading dose of 2g, followed by 600mg every 12
				hours) </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Interferon
				β group (n=11): Subcutaneous IFN-b1a (44mg) administered
				three-times weekly + ribavirin (loading dose of 2g, followed by
				600mg every 12 hours)  </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Treatment regimens were
			switched to IFN-b1a + ribavirin on 1 May 2014, following mortality
			reviews</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>4
				patients were switched from interferon α to interferon β</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Survival</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>32 patients hospitalized with MERS-CoV pneumonia</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Not randomized</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Methods not thoroughly
			described</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Follow-up
				period is unclear</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Inclusion
				and exclusion criteria not described</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Zhao Z, Zhang F, Xu M, et al.
			Description and clinical treatment of an early outbreak of severe
			acute respiratory syndrome (SARS) in Guangzhou, PR China. </B></FONT><FONT SIZE=2><I><B>J
			Med Microbiol. </B></I></FONT><FONT SIZE=2><B>2003;52(Pt
			8):715-720.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Are ribavirin, antibiotics, and/or </FONT><FONT COLOR="#00000a"><FONT SIZE=2>interferon</FONT></FONT><FONT SIZE=2>-a
			associated with improved clinical course and reduced mortality
			among patients with SARS-CoV-1?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Thirty-six cases
			developed ARDS </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>11/190
				died</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				response to antibiotics. </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>No benefit with
			ribavirin compared to other treatment arms with steroids &amp;
			non-invasive respiratory support</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				early resolution of pyrexia</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Resolution
					of fever at day 10–14, when regimen changed to quinolone,
					azithromycin, and methyl prednisolone 80–160 mg</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Most
				patients developed pulmonary infiltrates and increased shortness
				of breath within 7-10 days </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>12/40
				required supportive oxygen therapy </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>3
					received mechanical ventilation </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>2/40
				died of severe ARDS</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Best outcome in
			patients who received early use of high-dose steroids in
			combination with a quinolone + azithromycin </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Improvement
				of clinical symptoms and signs</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Decreased
				incidence of ARDS and mechanical ventilation </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Decreased
				mortality </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Randomized treatment
			trial in 190 patients with presumed SARS in Guangdong, China
			between January-February 2003</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patients
				admitted between February 2-4, 2003 were randomly to:</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>IV
					ribavirin 0.4 – 0.6 g daily + cefoperazone/sulbactam 2.0g
					twice daily (n=40)</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>IV
					fluoroquinolone + azithromycin 0.4 g daily + intramuscular
					recombinant interferon-a 3,000,000 U daily, and restricted use
					of steroids (n=30)</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>IV
					quinolone + azithromycin 0.4g daily (n=60) </FONT></FONT></FONT></FONT></FONT>
					</P>
					<UL>
						<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Some
						received recombinant interferon-a 3,000,000 and/or
						methylprednisolone</FONT></FONT></FONT></FONT></FONT></P>
					</UL>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patients
				presenting after February 14 (n=60) received IV levofloxacin 0.2g
				twice daily + azithromycin 0.6 g daily </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>45
					patients also received intramuscular recombinant interferon-a
					3,000,000 U daily</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Immunoglobulins,
				thymic peptides or recombinant human thymus proteins were given
				to 120 critically ill patients in all groups </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Clinical and laboratory features</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>190 infected patients
			with presumed SARS</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Case
				definition (120 cases satisfy all five criteria; 70 cases satisfy
				criteria 2–5) </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>History
					of recent (&lt;20 days) close contact with symptomatic patients</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Clinical
					symptoms and signs: acute onset of pyrexia (&gt;38·0 8C), with
					or without chills; headache, arthralgia, myalgia, fatigue or
					chest pain; cough, with or without sputum; clinical signs of
					pulmonary infection or dyspnea; ARDS</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Leukopenia/lymphopenia</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Chest
					X-ray or CT changes consistent with various degrees of pneumonia</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
					response to antibiotic treatment for typical/atypical pneumonia </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exclusion
				criteria: bacterial or fungal pneumonia, lung neoplasm,
				non-inflammatory pulmonary interstitial diseases, pulmonary edema
				and atelectasis, pulmonary thrombosis, eosinophilic pneumonitis
				or pulmonary vasculitis </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Unmeasured confounding</FONT></P>
			<P><FONT SIZE=2>Patients presenting after February 14 were not
			randomized</FONT></P>
		</TD>
	</TR>

</TABLE>
</details>

<details>
<summary><a name="LopinavirRitonavir">Lopinavir/Ritonavir</a></summary>

<TABLE WIDTH=88% CELLPADDING=7 CELLSPACING=0>
        <COL WIDTH=38*>
        <COL WIDTH=218*>

	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#212f57" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Lopinavir/Ritonavir</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT COLOR="#00000a"><FONT SIZE=2><B>Mechanism:</B></FONT></FONT><FONT COLOR="#0070c0"><FONT SIZE=2>
			</FONT></FONT><FONT COLOR="#00000a"><FONT SIZE=2>Combined protease
			inhibitor. I</FONT></FONT><FONT COLOR="#00000a"><FONT SIZE=2>nhibition
			of coronavirus polyprotein processing. Ritonavir is </FONT></FONT><FONT COLOR="#00000a"><FONT SIZE=2>a
			CYP3A4 inhibitor that boosts the activity of lopinavir by
			decreasing its metabolism by CYP3A4. </FONT></FONT>
			</P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Experimental
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-bottom: 0in"><FONT SIZE=2><B>Cao B,
			Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults
			Hospitalized with Severe Covid-19. </B></FONT>
			</P>
			<P ALIGN=CENTER><FONT SIZE=2><I><B>New England Journal of
			Medicine. </B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Is oral lopinavir–ritonavir safe and efficacious
			for treatment in hospitalized patients with SARS-CoV-2?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>LPV/r added to standard
			care was not associated with clinical improvement or mortality in
			seriously ill patients with COVID-19, when compared to standard
			care alone</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				significant between group differences in severity of illness or
				Day 1 clinical status </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>LPV/r
				treatment group had slightly higher mean Day 1 viral load
				(4.4±2.0 log</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>10</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>
				copies/mL) compared to the standard care arm (3.7±2.1 log</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>10</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>
				copies/mL)</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>ITT analysis: No
			difference in time to clinical improvement (median 16 days in both
			groups, HR for improvement 1.31; 95% CI 0.95-1.85)</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>LPV/r
				started within 12 days of symptom onset was </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2><U><B>not</B></U></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>&nbsp;found
				to be associated with a shorter time to clinical improvement
				(hazard ratio, 1.25; 95% CI, 0.77 to 2.05)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>mITT
				analyses (excluding 3 deaths prior to receipt of LPV/r): Modest
				but statistically significant difference of 1 day in time to
				clinical improvement</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Median
					time to clinical improvement 15 vs. 16 days (HR 1.39; 95% CI
					1.00-1.91).</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>28-day mortality was
			numerically lower in LPV/r group</FONT></P>
			<UL>
				<UL>
					<UL>
						<UL>
							<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>ITT population:
							19.2% vs. 25.0% (p&gt;0.05)</FONT></P>
							<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>mITT
							population: 16.7% vs. 25.0% (p&gt;0.05) </FONT>
							</P>
						</UL>
					</UL>
				</UL>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Throat swab viral RNA
			loads over time did not differ between the groups </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Did
				not differ when accounting for duration of symptoms</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Percentage
				of patients with detectable RNA for SARS-CoV-2 was comparable
				between groups at all sampling time points after Day 1 (includes
				Days 5, 10, 14, 21, and 28). </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P><FONT SIZE=2>LPV/r stopped early in 13 (13.5% or 1 in 7) due to
			adverse effects </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Open label randomized
			control trial conducted at Jin Yin-Tan Hospital in Wuhan China
			between January 8 and February 3, 2020</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				Arm (N=99): LPV/r 400 mg/100 mg PO q12h x 14 days + standard care
				</FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>LPV/r
					given as liquid via NGT for patients unable to swallow</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Control
				Arm (N=100): standard care alone </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Approximately
				one-third of patients in either arm received systemic
				glucocorticoids</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Intention to treat
			analyses (ITT) </FONT>
			</P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Modified
				intention to treat analyses (mITT): excluding 3 deaths prior to
				receipt of LPV/r</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Time
				to clinical improvement: defined as the time from randomization
				to 2-point improvement on a 7-point ordinal scale or hospital
				discharge, whichever occurred first</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Other
				outcomes: Clinical status on Days 7 and 14, 28-day mortality,
				safety, proportion with viral RNA detection over time, and viral
				RNA titer area-under-the-curve (AUC) measurement </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Seriously ill patients
			with confirmed SARS-CoV-2</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Inclusion:
				Adults ≥ 18 years old with radiographic pneumonia, SaO</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>2</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>
				≤94% on room air or PaO</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>2</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>:FiO</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>2</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>
				≤ 300 mmHg, SARS-CoV-2 positive by PCR  </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exclusion:
				Hypersensitivity, severe liver disease, contraindicated drug-drug
				interaction, pregnancy, breast-feeding, HIV infection</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Design</FONT></P>
			<UL>
				<UL>
					<UL>
						<UL>
							<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Open-label
							design may have introduced observer bias</FONT></P>
							<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Patients were
							late in disease course, so it is difficult to distinguish drug
							effect from natural history</FONT></P>
							<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Selective
							exclusion of 3 patients who died within 24 hours of
							randomization to LPV/r may have introduced bias, since a
							similar exclusion was not performed in the standard care arm</FONT></P>
							<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Misclassification
							bias: Potentially suboptimal SARS-CoV-2 RNA sampling methods
							(i.e. infrequent sampling and use of throat swabs)</FONT></P>
							<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Use of ordinal
							scale as outcome does not account for varying size of
							intervals</FONT></P>
						</UL>
					</UL>
				</UL>
			</UL>
			<P STYLE="margin-left: -0.02in; margin-bottom: 0in"><FONT SIZE=2>Analyses</FONT></P>
			<UL>
				<UL>
					<UL>
						<UL>
							<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Several
							confounding variables including receipt of glucocorticoid
							therapy, timing of LPV/r administration (early vs. late), and
							a slightly higher Day 1 viral load in the LPV/r group</FONT></P>
							<UL>
								<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Imbalance in
								baseline variables</FONT></P>
							</UL>
							<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Sample size and
							power calculations were revised during study, and the
							parameters are unclear</FONT></P>
							<UL>
								<LI><P><FONT SIZE=2>Study was underpowered to draw any
								conclusions from ITT findings</FONT></P>
							</UL>
						</UL>
					</UL>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Observational
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Deng L, Li C, Zeng Q, et al.
			Arbidol combined with LPV/r versus LPV/r alone against Corona
			Virus Disease 2019: A retrospective cohort study. </B></FONT><FONT SIZE=2><I><B>J
			Infect. </B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Is arbidol and lopinavir/ritonavir(LPV/r)
			treatment for patients with COVID-19 more effective than treatment
			with LPV/r only?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Combination therapy is
			associated with a significant decrease in detectable virus at 7
			and 14 days </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>7
				days: SARS-CoV-2 was undetectable in nasopharyngeal specimens in
				6/17 (35%) treated with LPV/r alone compared to 12/16 (75%)
				treated with LPV/r + arbidol </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>14
				days: SARS-CoV undetectable in in 9/17 (53%) treated with LPV/r
				alone compared to 15/16 (94%) treated with LPV/r + arbidol </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Combination therapy is
			associated with a significant improvement in pneumonia on imaging
			at 7 days </FONT>
			</P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>CT
				imaging demonstrated improvement in pneumonia among 5/17 (29%) in
				the LPV/r alone group compared to 11/16 (69%) in the LPV/r +
				arbidol group at 7 days </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective study
			among adults with COVID-19 conducted at the at The Fifth
			Affiliated Hospital of Sun Yat-Sen University between January 17
			and February 13, 2020</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				group (n=16):  LPV/r 400 mg/100 mg PO q12h + arbidol (influenza
				antiviral not licensed in the U.S.)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Control
				group (n=17): LPV/r 400 mg/100 mg PO q12h alone</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Negative conversion
			rate of coronavirus (day 7 and 14)</FONT></P>
			<P><FONT SIZE=2>Progression or improvement of pneumonia on chest
			CT (day 7)</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>All eligible patients with laboratory confirmed
			COVID-19</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective and
			non-randomized study</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Small size</FONT></P>
			<P><FONT SIZE=2>Unmeasured confounding</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Descriptive</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Young BE, Ong SWX, Kalimuddin S,
			et al. Epidemiologic Features and Clinical Course of Patients
			Infected With SARS-CoV-2 in Singapore. </B></FONT><FONT SIZE=2><I><B>JAMA.
			</B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Describe the epidemiology, clinical features, and
			treatment for patients with COVID-19.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Five patients with
			COVID-19 requiring supplemental O</FONT><SUB><FONT SIZE=2>2</FONT></SUB><FONT SIZE=2>
			in Singapore received “low dose” LPV/r 200 mg/100 mg q12h x 14
			days along with supportive care.</FONT><SUP><FONT SIZE=2>11</FONT></SUP></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Efficacy:
				Fever resolution in 1-3 days of LPV/r initiation </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>O</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>2</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>
					requirement: 3/5 (60%) experienced reduced O</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>2</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>
					requirement by day 3 while 2/5 (40%) had increasing demand,
					resulting in mechanical ventilation in 1 case</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Viral
				shedding: 2/5 (40%) were negative for viral shedding by day 2,
				1/5 (20%) cleared virus later in the admission, and 2/5 (40%) had
				persistent viral shedding throughout ICU admission </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Safety:
				Only 1/5 patients were able to complete the full 14-day course
				due to lack of adverse events</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>4/5
					(80%) developed significant GI adverse effects (N/V/D), 3/5
					(60%) developed significant LFT abnormalities</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Case series of clinical management of the first 18
			patients across 4 hospitals in Singapore who diagnosed with
			COVID-19</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Description of epidemiologic features, clinical
			presentation, treatment, and outcomes </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>The first 18 patients
			in Singapore with confirmed COVID-19 </FONT>
			</P>
			<P><BR>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Descriptive studies are
			hypothesis generating and cannot establish causal relationships</FONT></P>
			<P><FONT SIZE=2>Missing laboratory and baseline values</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Evidence in
			SARS-CoV-1 &amp; MERS-CoV&nbsp;</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Chan KS, Lai ST, Chu CM, et al.
			Treatment of severe acute respiratory syndrome with
			lopinavir/ritonavir: a multicentre retrospective matched cohort
			study. </B></FONT><FONT SIZE=2><I><B>Hong Kong Med J.
			</B></I></FONT><FONT SIZE=2><B>2003;9(6):399-406.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>What are the</FONT><FONT COLOR="#00000a"><FONT SIZE=2>
			</FONT></FONT><FONT SIZE=2>outcomes of patients with SARS treated
			with lopinavir/ritonavir (LPV/r), compared with a matched cohort
			who received standard treatment only?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Among
				44 patients with SARS-CoV-1 who received LPV/r + ribavirin as
				initial treatment for SARS-CoV-1, mortality (2.3%), intubation
				rate (0%), and pulse methylprednisolone usage (27.0%) were
				reduced compared to a matched “supportive care” cohort
				(15.6%, 11.0%, 55.0%, respectively)</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>LPV/r
					was initiated a median 5.5 days after symptom onset.</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				significant differences were observed when 31 SARS-CoV-1 patients
				receiving LPV/r monotherapy as salvage treatment (median 18 days
				after symptom onset) were compared to historical controls.</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective matched
			cohort study across four acute regional hospitals in Hong Kong</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				(n=75): </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Initial
					treatment (n=44): 10-14 days lopinavir 400 mg/ritonavir 100 mg
					orally every 12 hours, in addition to standard of care as
					initial treatment</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Rescue
					group (n=31): patients with worsening oxygen saturation,
					shortness of breath, and relevant radiological findings, failure
					of pulse steroid treatment </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Controls:
				Patients with SARS who had received standard treatment</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Initial
					treatment (n=634): matched on age, sex, co- morbidity, and
					initial LDH level within 5 days of onset of symptoms</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Rescue
					group: matched on age, sex, co-morbidity, maximal LDH level
					before the administration of pulse methylprednisolone, and the
					use of pulse methyl- prednisolone</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Standard
				of care: 10-14 days ribavirin (2.4 g oral loading dose, followed
				by 1.2 g orally every 8 hours, or 8 mg/kg intravenously every 8
				hours) + 21day corticosteroid taper (starting dose:
				hydrocortisone 100-200 mg every 6-8 hours)</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>pulses
					of methylprednisolone 500-1000 mg daily given intravenously were
					used as rescue therapy </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Death rate, percentage of patients with oxygen
			desaturation (inability to maintain normal saturation of ≥96%
			despite supplemental oxygen), airway intubation rate, and use of
			rescue pulse methylprednisolone </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Hospitalized patients with severe acute
			respiratory syndrome </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective study </FONT>
			</P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Confounding:
			co-morbidities were not classified according to severity</FONT></P>
			<P><FONT SIZE=2>Confounding by indication in rescue treatment
			group  </FONT>
			</P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Chan JF, Yao Y, Yeung ML, et al.
			Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves
			Outcome of MERS-CoV Infection in a Nonhuman Primate Model of
			Common Marmoset. </B></FONT><FONT SIZE=2><I><B>J Infect Dis.
			</B></I></FONT><FONT SIZE=2><B>2015;212(12):1904-1913.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does lopinavir improve outcomes in
			MERS-CoV-infected common marmosets?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Therapeutic LPV/r ±
			IFN-b in marmosets resulted in improved clinical scores, less
			weight reduction, and less pulmonary infiltrate</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Control
				and MMF-treated animals developed severe illness</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>None
				of the lopinavir/ritonavir- treated and interferon-β1b-treated
				animals developed severe symptoms</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>1
					lopinavir/ritonavir-treated animal died unexpectedly during
					anesthesia at 24 hours</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>lopinavir/ritonavir-treated:
					normal CXR findings in the &amp; mildest macroscopic lung
					lesions</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>lopinavir/ritonavir-treated:
					lowest mean viral load in necropsied lungs </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>0% tissue culture
			infectious dose (TCID50) per mL was determined for MERS-CoV in
			VeroE6 cells </FONT>
			</P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo: 12 healthy
			male common marmosets inoculated with 5 × 106 TCID50 of MERS-CoV
			and randomly (non-blinded) assigned to one of 4 treatment groups</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Control
				(n=3): sham treatment</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				(n=3): mycophenolate mofetil (MMF) </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				(n=3): lopinavir/ritonavir </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				(n=3): recombinant interferon- β1b </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P><FONT SIZE=2>Necropsies were scheduled at 72 hours post
			innoculation</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Clinical and vital signs, histopathology,
			immunohistochemistry, and viral load</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>VeroE6 cells </FONT>
			</P>
			<P><FONT SIZE=2>12 healthy male common marmosets </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>In vivo activity in non-human primates is an
			imperfect analogue to humans</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Chen F, Chan KH, Jiang Y, et al.
			In vitro susceptibility of 10 clinical isolates of SARS
			coronavirus to selected antiviral compounds. </B></FONT><FONT SIZE=2><I><B>J
			Clin Virol. </B></I></FONT><FONT SIZE=2><B>2004;31(1):69-75.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Do lopinavir and ritonavir have in vitro antiviral
			activity against clinical isolates of SARS coronavirus?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Ritonavir did not
			demonstrate inhibitory activity during initial screening against
			prototype virus grown in the fRhK-4 cell line</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Lopinavir had
			detectable antiviral activities in the fRHK-4 cell lines </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>LPV </FONT><FONT SIZE=2><I>in
				vivo</I></FONT><FONT SIZE=2> concentrations: peak (9.6 mg/mL) and
				trough (5.5 mg/mL)</FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>LPV EC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>
				against SARS-CoV-1 (6 mg/mL) by plaque reduction assay</FONT></P>
			</UL>
			<UL>
				<LI><P><FONT SIZE=2>Activitiy decreased with incubation beyond
				48h </FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Ten isolates of SARS
			coronavirus from 10 different SARS collected from different
			patients from different hospitals of the Hong Kong Special
			Administrative Region</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Isolated
				from the lung tissue biopsy, urine, and nasopharyngeal aspirate </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P><FONT SIZE=2>Antiviral activity of commercially available drugs
			tested in vitro</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Inhibition of the cytopathic effect (CPE) at 48
			and 72 h</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>fetal rhesus kidney4
			(fRHK-4) cell lines</FONT></P>
			<P><FONT SIZE=2>Vero-E6 cell lines </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Difficult to extrapolate in vivo activity and
			dosing from in vitro experiments</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-bottom: 0in"><FONT SIZE=2><B>Chu CM,
			Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the
			treatment of SARS: initial virological and clinical findings. </B></FONT>
			</P>
			<P ALIGN=CENTER><FONT SIZE=2><I><B>Thorax. </B></I></FONT><FONT SIZE=2><B>2004;59(3):252-256.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Do patients with SARS have improved clinical and
			virologic response when treated with combination
			lopinavir/ritonavir + ribavirin (RBV) versus ribavirin
			monotherapy?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Patients treated with
			combination lopinavir/ritonavir + RBV had improved clinical and
			virologic response, compared to RBV controls</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Milder
				disease course (diarrhea, recurrence of fever, and chest
				radiographs)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Progressive
				decrease in viral load</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Significantly
				lower rates of ARDS &amp; mortality at 21 days (2.4% v 28.8%,
				p=0.001)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"> <FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Fewer
				nosocomial infections </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Mild adverse events in
			treatment arm (n=11): GI upset, liver dysfunction, headache &amp;
			blurred vision </FONT>
			</P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Hgb
				dropped </FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2><U>&gt;</U></FONT></FONT><FONT FACE="Arial, serif"><FONT SIZE=2>
				2g/dL in 29 patients receiving LPV/r + RBV</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Open trial of a
			combination of a lopinavir/ritonavir versus control between 24
			March and 28 April 2003</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>All
				patients received 14 days of RBV: 4g oral loading dose, followed
				by 1.2 g every 8 hours</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>If
					patient could not tolerate oral RBV, received IV 8mg/kg every 8
					hours</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"> <FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>All
				patients received a reducing regimen of corticosteroid for 21
				days</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Starting
					dose: hydrocortisone 100–200 mg every 6–8 hours or
					methylprednisolone 3 mg/kg/day</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patients
					who developed dyspnea or hypoxia received pulses of intravenous
					methylprednisolone (0.5–1 g/day up to 4 g) </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
				group additionally received a combination of oral lopinavir (400
				mg)/ritonavir (100 mg) every 12 hours for 14 days </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Initial
					treatment subgroup (n = 12): lopinavir/ritonavir started before
					pulse methylprednisolone </FONT></FONT></FONT></FONT></FONT>
					</P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Rescue
					treatment subgroup (n = 29): lopinavir/ritonavir started after
					pulse methylprednisolone </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>152
				patients</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Historical
					controls (n=111): Patients treated before April 16, 2003</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Treatment
					group (n=41): Patients presenting after April 16, 2003</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Serial
				quantitative RT-PCR performed on days 5, 10, 15, and 20 after
				onset of symptoms </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Follow-up:
				3 weeks were treated with a combination of lopinavir/ritonavir
				and ribavirin</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Clinical progress &amp; virologic outcomes</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>152 consecutive
			patients with probable SARS </FONT>
			</P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exclusion
				criteria: development of ARDS</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Not randomized</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Imbalance
				in baseline characteristics between groups</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P><FONT SIZE=2>Unmeasured confounders</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Sheahan TP, Sims AC, Leist SR, et
			al. Comparative therapeutic efficacy of remdesivir and combination
			lopinavir, ritonavir, and interferon beta against MERS-CoV. </B></FONT><FONT SIZE=2><I><B>Nat
			Commun. </B></I></FONT><FONT SIZE=2><B>2020;11(1):222.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does Remdesivir (GS- 5734), in comparison to
			combination lopinavir, ritonavir and interferon beta, have
			comparable in vitro and in vivo antiviral efficacy against
			MERS-CoV? </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>When compared with
			combination lopinavir, ritonavir and interferon beta, Remdesivir
			demonstrated superior antiviral activity against MERS-CoV in vitro
			and in vivo.</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Potent inhibition
				of MERS-CoV replication with an EC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>&nbsp;of
				0.09 µM, no observable cytotoxicity up to 10μM, and a
				selectivity index &gt; 100</FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Superior in vitro
				antiviral activity compared with lopinavir and ritonavir</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Significant
				decrease in weight loss, plaque forming units</FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Pre-exposure
				prophylaxis: significantly reduced mortality, lung hemorrhage,
				and viral lung titers</FONT></P>
				<UL>
					<LI><P><FONT SIZE=2>Significantly reduced lung injury scores</FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Parallel
				antiviral assays assessing antiviral efficacy and cytotoxicity in
				the Calu-3 human lung cell line&nbsp;</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Efficacy
				of prophylactic Remdesivir, compared to vehicle and combination
				therapy, in a new transgenic mouse model of MERS-CoV pathogenesis</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Single
				therapeutic efficacy study with a lethal dose of MERS-CoV</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro antiviral
			efficacy:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Inhibition of
				viral replication: half-maximum effective concentration,
				cytotoxicity</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo antiviral
			efficacy:</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Weight
				loss, survival, viral titers, pulmonary pathology, American
				Thoracic Society lung injury score</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro: Calu-3 cell
			line</FONT></P>
			<P><FONT SIZE=2>In-vivo: </FONT><FONT SIZE=2><I>Ces1c</I></FONT><SUP><FONT SIZE=2>−/−</FONT></SUP><FONT SIZE=2>&nbsp;</FONT><FONT SIZE=2><I>hDPP4</I></FONT><FONT SIZE=2>&nbsp;mouse
			model</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Difficult to
			extrapolate in vivo activity and dosing from in vitro experiments</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vivo activity in
			animal model is an imperfect analogue to humans</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Window
				for therapeutic administration after the onset of symptoms but
				prior to the peak of virus replication differs between humans and
				mouse model </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Yamamoto N, Yang R, Yoshinaka Y,
			et al. HIV protease inhibitor nelfinavir inhibits replication of
			SARS-associated coronavirus. </B></FONT><FONT SIZE=2><I><B>Biochem
			Biophys Res Commun. </B></I></FONT><FONT SIZE=2><B>2004;318(3):719-725.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>To identify anti-SARS drugs available for clinical
			use.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Individually, ritonavir
			and lopinavir did not affect the replication of SARS-CoV
			(effective concentration [EC</FONT><SUB><FONT SIZE=2>50</FONT></SUB><FONT SIZE=2>]
			not calculable)</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Ritonavir
				cytotoxic concentration (CC</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>):
				9.63 (3.11) </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Lopinavir
				cytotoxic concentration (CC</FONT></FONT><SUB><FONT FACE="Arial, serif"><FONT SIZE=2>50</FONT></FONT></SUB><FONT FACE="Arial, serif"><FONT SIZE=2>):
				24.15 (5.01) </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro study of Vero
			cells infected with FFM-1 strain of SARS-CoV-1 and treated with
			antivirals</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Pre-entry:
				Cells pretreated with antivirals for 3 hours</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Time
				of addition: Drugs administered at the time of infection or 3 h
				after infection </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Quantification of SARS-CoV RNA </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Vero E6 cells </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Difficult to extrapolate in vivo activity and
			dosing from in vitro experiments</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Zhang XW, Yap YL. Old drugs as
			lead compounds for a new disease? Binding analysis of SARS
			coronavirus main proteinase with HIV, psychotic and parasite
			drugs. </B></FONT><FONT SIZE=2><I><B>Bioorg Med Chem.
			</B></I></FONT><FONT SIZE=2><B>2004;12(10):2517-2521.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>To predict the binding pockets and affinities of
			SARS-CoV-1with existing drugs.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Individually, lopinavir
			and ritonavir have weak in vitro activity against SARS-CoV </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Ritonavir
				had the highest binding affinity to the substrate binding site of
				SARS-CoV proteinase </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>The
				inhibitory constant of ritonavir was greater than lopinavir</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro silico binding
			studies to provide information for anti-SARS inhibitor design </FONT>
			</P>
			<P><BR>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Binding affinity &amp; inhibition</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>N/A</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Difficult to extrapolate in vivo activity and
			dosing from in vitro experiments</FONT></P>
		</TD>
	</TR>

</TABLE>
</details>

<details>
<summary><a name="Corticosteroids">Corticosteroids</a></summary>

<TABLE WIDTH=88% CELLPADDING=7 CELLSPACING=0>
        <COL WIDTH=38*>
        <COL WIDTH=218*>

	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#212f57" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Corticosteroids</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT COLOR="#00000a"><FONT SIZE=2><B>Mechanism: </B></FONT></FONT><FONT SIZE=2>Theoretically
			reduces inflammatory-induced lung injury and reduces cytokine
			storm.   </FONT>
			</P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Observational
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Wu C, Chen X, Cai Y, et al. Risk
			Factors Associated with Acute Respiratory Distress Syndrome and
			Death in Patients With Coronavirus Disease 2019 Pneumonia in
			Wuhan, China. </B></FONT><FONT SIZE=2><I><B>JAMA Internal
			Medicine. </B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>What risk factors (including treatment with
			methylprednisolone) are associated with the development of ARDS
			and progression to death?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Treatment with
			methylprednisolone may be beneficial for patients who develop ARDS
			</FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>84
				(42%) patients developed ARDS</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Factors
					associated with development of ARDS: Age ≥65 years, fever ≥39
					°C, hypertension, diabetes, neutrophilia, lymphocytopenia, CD3
					and CD4 T-cell counts, LFTs, prealbumin, creatinine, glucose,
					LDH, low-density lipoprotein, serum ferritin, PT, and D-dimer </FONT></FONT></FONT></FONT></FONT>
					</P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a">
					<FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Compared
					with patients who did not have ARDS, patients who developed ARDS
					were less likely to be treated with antiviral therapy (-14.4%
					difference, 95% CI -26% to -2.9%; p= 0.005)</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>52%
				mortality in ARDS group</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>All
					patients who died had developed ARDS </FONT></FONT></FONT></FONT></FONT>
					</P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Factors
					associated with death among patients with ARDS: older age,
					neutrophilia, LDH, D-dimer, IL-6</FONT></FONT></FONT></FONT></FONT></P>
					<UL>
						<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Fever
						≥39 °C negatively associated with death</FONT></FONT></FONT></FONT></FONT></P>
					</UL>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Methylprednisolone:
				among patients with ARDS, treatment with methylprednisolone
				decreased risk of death (HR 0.38, 95% CI 0.2-0.72, p=0.003) </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"> <FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>46%
					receiving steroids died vs 61.8% without steroids</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patients
					who received steroids appeared to be sicker, as defined by a
					higher grade on Pneumonia Severity Index</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective cohort
			study of 201 patients with confirmed COVID-19 pneumonia in Wuhan,
			China, admitted between December 25, 2019 and January 26</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Time
				to event: defined as the time from hospital admission to event
				(ARDS or death)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Reported
				treatments:</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>170
					(85%) received antiviral treatment, including oseltamivir (134
					[67%]), ganciclovir (81 [40%]), lopinavir/ritonavir (30 [15%]),
					and interferon alfa (22 [11%])</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>196
					(97%) received empiric antibiotics</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>106
					(52.7%) received antioxidant therapy, including glutathione and
					N-acetyl-L-cysteine</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>62
					(31%) received methylprednisolone </FONT></FONT></FONT></FONT></FONT>
					</P>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>70
					(35%) received immunomodulators, including immunoglobulin,
					thymosin, and recombinant human granulocyte colony stimulating
					factor</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Development
				of ARDS </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Death
				among patients who developed ARDS </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>99 patients with RT-PCR
			confirmed SARS-CoV-2 admitted to Jinyintan Hospital in Wuhan,
			China </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>10
				had previously been described in descriptive studies by Chen et
				al</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2>38</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2>
				and Huang et al</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2>39</FONT></FONT></SUP></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>On
				chest imaging: 10 (5%) had unilateral infiltrates and 191 (95%)
				had bilateral infiltrates </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>66
				(33%) patients with underlying chronic diseases</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Analyses:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Short
				follow-up: 13 (6.5%) patients were still hospitalized at time of
				writing, limiting analyses of outcome</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Missing
				data for each variable were handled by complete case analysis,
				which may bias estimates</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Incomplete
				testing for other viral, fungal, and/or bacterial respiratory
				infections</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Confounding:</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Confounding
					by indication in receipt of corticosteroids</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Models
					do not appear to have adjusted for potential confounders</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Descriptive
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Chen N, Zhou M, Dong X, et al.
			Epidemiological and clinical characteristics of 99 cases of 2019
			novel coronavirus pneumonia in Wuhan, China: a descriptive study.
			</B></FONT><FONT SIZE=2><I><B>Lancet. </B></I></FONT><FONT SIZE=2><B>2020;395(10223):507-513.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>What are the clinical and epidemiologic features
			of COVID-19?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Report clinical
			characteristics and treatment course </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>19
				received corticosteroids for 3-15 days (median, 5 days) </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>At
				the time of writing, 31 (31%) patients were discharged, 57 (58%)
				remained hospitalized, and 11 (11%) had died</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Oxygen
				requirements: 75 (76%)</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>17
					(17%) required mechanical ventilation for 4–22 days (median 9
					days [IQR 7–19])</FONT></FONT></FONT></FONT></FONT></P>
					<UL>
						<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Four
						required invasive ventilation (still required ventilation at
						data cutoff) </FONT></FONT></FONT></FONT></FONT>
						</P>
					</UL>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Retrospective
			descriptive study (case series) of all confirmed cases of
			SARS-CoV-2 in Wuhan Jinyintan Hospital, admitted between January 1
			and January 20, 2020 </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Clinical
				outcomes were followed up to January 25, 2020 </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Reported
				treatments:</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>75
					(76%) received antiviral treatment, including oral oseltamivir
					(75 mg every 12 hours), IV ganciclovir (0.25 g every 12 hours),
					and lopinavir and ritonavir tablets (500 mg twice daily, orally)</FONT></FONT></FONT></FONT></FONT></P>
					<UL>
						<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Duration:
						3–14 days (median 3 days [IQR 3–6])</FONT></FONT></FONT></FONT></FONT></P>
					</UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>70
					(71%) received antibiotics: 25 (25%) patients received a single
					antibiotic and 45 (45%) patients received combination therapy </FONT></FONT></FONT></FONT></FONT>
					</P>
					<UL>
						<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Duration:
						3–17 days (median 5 days [IQR 3–7])</FONT></FONT></FONT></FONT></FONT></P>
					</UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>19
					(19%) received glucocorticoids (methylprednisolone sodium
					succinate, methylprednisolone, and dexametha&shy;sone) </FONT></FONT></FONT></FONT></FONT>
					</P>
					<UL>
						<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Duration:
						3–15 days (median 5 [3–7])</FONT></FONT></FONT></FONT></FONT></P>
					</UL>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Epidemiology and clinical characteristics of
			COVID-19.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>99 patients with RT-PCR
			confirmed SARS-CoV-2 admitted to Jinyintan Hospital in Wuhan,
			China </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>49
				(49%) had a history of exposure to the Huanan seafood market</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>47
					had a history of long-&shy;term exposure </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>50
				(51%) patients with underlying chronic diseases</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>33
				(33%) presented with organ function damage, including 17 (17%)
				with ARDS and eight (8%) with acute respiratory injury</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Descriptive studies are
			hypothesis generating and cannot establish causal relationships</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Short
				follow-up: 58% of patients were still hospitalized at the time of
				analyses, limiting outcome data</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Outcomes
				were not stratified by treatment: Cannot compare cases</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Huang C, Wang Y, Li X, et al.
			Clinical features of patients infected with 2019 novel coronavirus
			in Wuhan, China. </B></FONT><FONT SIZE=2><I><B>Lancet.
			</B></I></FONT><FONT SIZE=2><B>2020;395(10223):497-506.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>How do the clinical features of COVID-19 differ
			between intensive care unit (ICU) and non-ICU patients?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Report clinical
			characteristics and treatment course </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>9
				received corticosteroids </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>At
				the time of writing, 28 (68%) patients were discharged, 7 (27%)
				remained in the hospital, and 6 (15%) had died</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Oxygen
				requirements: 75 (76%)</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>17
					(17%) required mechanical ventilation for 4–22 days (median 9
					days [IQR 7–19])</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Compared
				with non-ICU patients, ICU patients had higher levels of
				cytokines (IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and
				TNF-alpha) </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Nine
				(22%) patients were given systemic corticosteroids</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>6
					(67%) were ICU patients:</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>4
					(44%) died, compared to 2 (6.3%) patients who did not receive
					corticosteroids </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>All
				patients required some degree of oxygen support</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>4
					(10%) required invasive mechanical ventilation </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Prospective descriptive
			study of confirmed SARS-CoV-2 cases in Wuhan, China, admitted from
			December 31, 2019 to January 2, 2020</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Clinical
				outcomes were followed up to January 2, 2020</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Reported
				treatments:</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>38
					(93%) received antiviral treatment, oseltamivir (orally 75 mg
					twice daily) </FONT></FONT></FONT></FONT></FONT>
					</P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>41
					(100%) received empiric antibiotics</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>9
					(22%) received methylprednisolone 40–120 mg per day for severe
					community-acquired </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Epidemiology and clinical characteristics of
			COVID-19.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Of 59 suspected cases,
			41 patients with RT-PCR confirmed SARS-CoV-2</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>27
				(66%) had a history of exposure to the Huanan seafood market</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>All
				patients were diagnosed with pneumonia</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>13
				(32%) were admitted to the ICU for increased oxygen support </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Descriptive studies are
			hypothesis generating and cannot establish causal relationships</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Timing
				of administration of corticosteroids in treatment course is
				unknown</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Short
				follow-up: 27% of patients were still hospitalized at the time of
				analyses, limiting outcome data</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Evidence in
			SARS-CoV-1 &amp; MERS-CoV&nbsp;</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Arabi YM, Mandourah Y, Al-Hameed
			F, et al. Corticosteroid Therapy for Critically Ill Patients with
			Middle East Respiratory Syndrome. </B></FONT><FONT SIZE=2><I><B>Am
			J Respir Crit Care Med. </B></I></FONT><FONT SIZE=2><B>2018;197(6):757-767.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Is corticosteroid therapy associated with
			mortality and MERS coronavirus RNA clearance in critically ill
			patients with MERS?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>151 (49%) received
			corticosteroids (median initiation following admission to ICU, 3
			days [IQR, 1-7 days])</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Corticosteroid therapy
			was not associated with a difference in mortality, after
			adjustment for time-varying confounders </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Higher
				90-day crude mortality associated with corticosteroids: 112
				(74.2%) vs. 91 (57.6%; P = 0.002)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>No
				difference in adjusted analyses: adjusted odds ratio, 0.75 (95%
				confidence interval, 0.52–1.07; P = 0.12) </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Corticosteroids were
			associated with a longer median (IQR) ICU and hospital length of
			stay</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>ICU
				length of stay: 12.5 days (8.0–23.0 days) versus 7.0 (5.0–13.0
				days; P&lt;0.0001)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Hospital
				length of stay: 21.0 days (13.0–38.0 days) versus 15.0 days
				(8.0–30.0 days; P = 0.0006) </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P><FONT SIZE=2>Corticosteroid use was associated with delay in
			MERS coronavirus RNA clearance (adjusted HR, 0.35; 95% CI,
			0.17–0.72; P = 0.005) </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Multicenter,
			retrospective cohort study across 14 tertiary care hospitals in
			Saudi Arabia </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exposure:
				system corticosteroid therapy</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Preparations
					converted to hydrocortisone-equivalent doses (methylprednisolone
					1:5, dexamethasone 1:25, prednisolone 1:4) </FONT></FONT></FONT></FONT></FONT>
					</P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Primary
				outcome: 90-day all- cause mortality </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Secondary
				outcome: Length of stay in the ICU and hospital</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Time
				to MERS-CoV RNA clearance in respiratory secretions: time from
				ICU admission until the test was negative on two occasions,
				without a positive test afterward</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Only
				performed among patients who had ≥1 follow-up RT-PCR after the
				diagnostic test</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>All patients (309) with
			MERS admitted to the ICU between September 2012 and October 2015</FONT></P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Exclusion
				Criteria: </FONT></FONT><FONT COLOR="#000000"><FONT FACE="Arial, serif"><FONT SIZE=2>receiving
				chronic corticosteroid therapy before the onset of critical
				illness</FONT></FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Confounding: unmeasured
			confounders &amp; confounding by indication</FONT></P>
			<P><FONT SIZE=2>Not all patients received follow-up MERS-CoV RNA
			testing </FONT>
			</P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Stockman LJ, Bellamy R, Garner P.
			SARS: systematic review of treatment effects. </B></FONT><FONT SIZE=2><I><B>PLoS
			Med. </B></I></FONT><FONT SIZE=2><B>2006;3(9):e343.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Are corticosteroids associated with morbidity &amp;
			mortality benefit inpatients with SARS-CoV-1?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Inconclusive evidence
			of benefit in SARS, with some evidence of adverse events </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>SARS-infected
				patient: 25/29 were inconclusive</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>4
					were classified as causing possible harm</FONT></FONT></FONT></FONT></FONT></P>
					<UL>
						<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Evidence
						of avascular necrosis and steroid-induced psychosis in SARS
						patients </FONT></FONT></FONT></FONT></FONT>
						</P>
					</UL>
				</UL>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>ARDS: 2/3 trial
			indicated that high-dose methylprednisolone for 2 days was not
			effective for early ARDS </FONT>
			</P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>One
				small RCT of lower dose methylprednisolone (2 mg/kg per day),
				tapered after 2 weeks, found possible evidence of ARDS
				improvement </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Systematic review
			designed to summarize available evidence on the effects of
			ribavirin, lopinavir and ritonavir, corticosteroids, type I IFN,
			intravenous immunoglobulin (IVIG), or convalescent plasma in SARS
			and ARDS, regarding:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>In
				vivo studies of ≥10 patients treated for SARS, including
				randomized controlled trials (RCT), prospective uncontrolled
				study design, retrospective cohort design, case-control design,
				case series</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Studies
				of ARDS or acute lung injury among ≥20 patients, including RCT
				or systematic review</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<OL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Mortality
				or morbidity in SARS patients</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Effects
				on ARDS in adult patients</FONT></FONT></FONT></FONT></FONT></P>
			</OL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>In vitro evidence: 15
			studies</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Clinical evidence of
			SARS treatment in humans: 54 studies (37 in English, 17 in
			Chinese)</FONT></P>
			<P><FONT SIZE=2>ARDS: 3 studies </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Wide variance in
			treatment regimens</FONT></P>
			<P><FONT SIZE=2>Studies were largely inconclusive</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Evidence in
			Influenza</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT SIZE=2><B>Lansbury L, Rodrigo C,
			Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as
			adjunctive therapy in the treatment of influenza. </B></FONT><FONT SIZE=2><I><B>Cochrane
			Database Syst Rev. </B></I></FONT><FONT SIZE=2><B>2019;2:Cd010406.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Assess effectiveness and potential adverse effects
			of corticosteroids as adjunctive therapy in the treatment of
			influenza </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Corticosteroid therapy
			was associated with increased mortality </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Odds
				ratio (OR): 3.90 (95% CI, 2.31 to 6.60; I2 = 68%; 15 studies)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Stratified
				analysis of studies reporting adjusted estimates: OR 2.23 (95% CI
				1.54 to 3.24; I2 = 0%; 5 studies)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Pooled
				analysis of six studies reporting adjusted hazard ratios (HRs):
				1.49 (95% CI 1.09 to 2.02; I2 = 69%)</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Increased odds of
			hospital-acquired infection related to corticosteroid therapy were
			found on pooled analysis of seven studies</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Pooled
				OR 2.74 (95% CI 1.51 to 4.95; I2 = 90%)</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Low
				certainty grade: all were unadjusted estimates </FONT></FONT></FONT></FONT></FONT>
				</P>
			</UL>
			<P><FONT SIZE=2>Currently available evidence is insufficient to
			determine the effectiveness of corticosteroids for people with
			influenza</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Meta-analysis of
			randomized controlled trials (RCTs), quasi-RCTs, and observational
			studies that compared corticosteroid treatment with no
			corticosteroid treatment for influenza or influenza-like illness</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Pooled
				estimates of effect using a random-effects model</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Certainty
				of the evidence assessed using the GRADE framework</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<OL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Mortality</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Secondary
				infection</FONT></FONT></FONT></FONT></FONT></P>
			</OL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT FACE="Times New Roman, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Studies
			comparing additional steroid treatment with no additional steroid
			treatment in individuals with influenza </FONT></FONT></FONT></FONT>
			</P>
			<UL>
				<LI><P><FONT FACE="Times New Roman, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>30
				studies with 99,224 individuals </FONT></FONT></FONT></FONT>
				</P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Majority of evidence
			was from observational studies </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Only one RCT with
				24 patients with confirmed influenza infection </FONT>
				</P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Differences in
			measurement &amp; reporting across studies:</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Inconsistent
				reporting of important variables: time to hospitalization; use
				and timing of antiviral drugs and antibiotics; type, dose,
				timing, and duration of corticosteroid therapy </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Indications
				for corticosteroid therapy were not fully specified in many of
				the studies </FONT></FONT></FONT></FONT></FONT>
				</P>
				<UL>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Confounding
					by indication in many studies: association between
					corticosteroids and the presence of potentially confounding
					factors, such as disease severity and underlying illnesses</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>

</TABLE>
</details>

<details>
<summary><a name="Tocilizumab">Tocilizumab</a></summary>

<TABLE WIDTH=88% CELLPADDING=7 CELLSPACING=0>
        <COL WIDTH=38*>
        <COL WIDTH=218*>


	<TR>
		<TD COLSPAN=2 WIDTH=100% HEIGHT=10 BGCOLOR="#212f57" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER><FONT COLOR="#ffffff"><FONT SIZE=2><B>Tocilizumab</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#ffffff" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-right: 0.36in; margin-bottom: 0in"><FONT SIZE=2><B>Mechanism</B></FONT><SUP><FONT SIZE=2><B>51-54</B></FONT></SUP><FONT SIZE=2>:
			Tocilizumab is a recombinant, humanized, anti-human IL-6 receptor
			monoclonal antibody that binds and inhibits soluble and membrane
			bound IL-6 receptors, thereby inhibiting signal transduction.
			Reduction in IL-6 levels is believed to curb inflammatory response
			and associated sequelae of inflammation. </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-right: 0.36in; margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>The
				pathogenesis of SARS, MERS, and COVID-19 have all been associated
				with occurrence of cytokine storm and elevation of interleukins,
				tumor necrosis factor, etc. &amp; IL-6 has been identified as
				being elevated with all 3 coronavirus strains. </FONT></FONT></FONT></FONT></FONT>
				</P>
				<LI><P STYLE="margin-right: 0.36in; margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Severe
				COVID-19 disease is associated with a cytokine profile resembling
				haemophagocytic lymphohistiocytosis (sHLH; increased IL-2, IL-7,
				G-CSF, IFN-gamma inducible protein 10, monocyte chemoattractant
				protein 1, macrophage inflammatory protein 1-alpha, and
				TNF-alpha)</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<LI><P STYLE="margin-right: 0.36in; margin-bottom: 0in"><FONT SIZE=2>Predictors
				of mortality in 150 cases of COVID-19 included:</FONT></P>
				<UL>
					<LI><P STYLE="margin-right: 0.36in; margin-bottom: 0in"><FONT SIZE=2>Elevated
					ferritin: mean 1298 ng/mL in non-survivors vs. 614 ng/mL in
					survivors (p&lt;0.001)</FONT></P>
					<LI><P STYLE="margin-right: 0.36in"><FONT SIZE=2>Elevated IL-6
					on admission: median 11 pg/mL in non-survivors vs. 6.3 pg/mL in
					survivors (p&lt;0.0001)</FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-right: 0.36in"><FONT COLOR="#ffffff"><FONT SIZE=2><B>Observational
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: 0.18in; margin-right: 0.36in"><FONT SIZE=2><B>Xu
			X, Han M, Li T, et al. Effective Treatment of Severe COVID-19
			Patients with Tocilizumab. In: </B></FONT><FONT SIZE=2><I><B>ChinaXiv:
			20200300026.</B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does tocilizumab have efficacy in patients with
			severe SARS-CoV-2?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Clinical: All
				patients became afebrile on the 1</FONT><SUP><FONT SIZE=2>st</FONT></SUP><FONT SIZE=2>
				day after receiving tocilizumab and remained stable until the end
				of the observation period </FONT>
				</P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Oxygenation: 75%
					had decreased O2 requirements compared to baseline</FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>CT scan: Lesions
				absorbed in 19 of 21 (90.5%) patients </FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Laboratory:
				Percentage of lymphocytes returned to normal in 52.6% patients
				(10/19) within five days of tocilizumab </FONT>
				</P>
				<UL>
					<LI><P><FONT SIZE=2>CRP also returned to normal in 84.2% (16/19)</FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Multicenter retrospective single-arm observational
			study of patients receiving IV Tocilizumab in 2 hospitals in
			China.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Improvement in: </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Clinical features:
				Body temperature, oxygen saturations </FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>CT scan:
				Resolution of ground-glass opacities, focal consolidations</FONT></P>
				<LI><P><FONT SIZE=2>Laboratory: White blood cell count
				(lymphocyte %), CRP, Procalcitonin</FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>21 Patients with
			SARS-CoV-2 (17 patients severe &amp; 4 critical)</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Severity:
				(1) respiratory rate ≥ 30 breaths/min; (2) SpO2 ≤ 93% while
				breathing room air; (3) PaO2/FiO2 ≤ 300 mmHg</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Critical
				case: (1) respiratory failure requiring mechanical ventilation;
				(2) shock; (3) organ failure, (4) ICU admission</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>On Presentation: </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Clinical:
				Fever (100%), dry cough (66.7%), fatigue: 28.6%, dyspnea: 28.6%</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Oxygen
					requirement (20 [95.2]): High-flow (45%), nasal cannula (35%),
					mask O2 (5%), non-invasive ventilation (5%), Invasive
					ventilation (10%)</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>CT
				scan: All had abnormal chest CT on presentation: plaque like,
				ground-glass opacities, focal consolidations</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Ground glass
					opacities increased in size, extent, and severity in all 21
					patients within the first 7 days after admission</FONT></P>
				</UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Laboratory:
				Abnormal white blood cell count (20.0%; mean, 6.30 ± 2.77×109
				/L); decreased lymphocyte % (85.0%; mean, 15.52 ± 8.89%);
				increased CRP (100%; mean, 75.06 ± 66.80 mg/L); abnormal
				procalcitonin (10%; median, 0.33 ± 0.78 ng/mL)</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Received routine
			standard of care for 1 week prior to tocilizumab</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>7</FONT></FONT><SUP><FONT FACE="Arial, serif"><FONT SIZE=2>th</FONT></FONT></SUP><FONT FACE="Arial, serif"><FONT SIZE=2>
				provisional edition: Novel Coronavirus Pneumonia Diagnosis and
				Treatment Plan:</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<UL>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Lopinavir/ritonavir:
					400/100 mg twice daily for up to 10 days</FONT></P>
					<LI><P><FONT SIZE=2>Methylprednisolone 1-2 mg/kg/day for 3-5
					days</FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Design</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Non-randomized,
				observational study</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Participants</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Small sample size,
				only 4 patients deemed to be critically ill</FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>No comparator
				group</FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Treatment</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patient
				weights were not reported. It is therefore unclear what the
				rationale was for using a dose of 400 mg</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Presence
				of confounding variables, including treatment with
				methylprednisolone therapy</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Interpretation of
			results</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Patients also
				received “standard of care” treatment with other
				anti-inflammatory modulators, which limits interpretability of
				effect of tocilizumab</FONT></P>
				<LI><P><FONT SIZE=2>Results reported at 5 days post Tocilizumab
				dose, however, unclear how long these patients were followed</FONT></P>
			</UL>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% BGCOLOR="#404040" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-right: 0.36in"><FONT COLOR="#ffffff"><FONT SIZE=2><B>Descriptive
			Studies</B></FONT></FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: 0.18in; margin-right: 0.36in"><FONT SIZE=2><B>Ferrey
			AJ, Choi G, Hanna RM, et al. A Case of Novel Coronavirus Disease
			19 in a Chronic Hemodialysis Patient Presenting with
			Gastroenteritis and Developing Severe Pulmonary Disease. </B></FONT><FONT SIZE=2><I><B>American
			Journal of Nephrology. </B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does tocilizumab have efficacy in patients with
			SARS-CoV-2?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Care is still ongoing</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Case study of a
			56-year-old gentleman with ESRD who was admitted 2 months after
			travel to South Korea with worsening shortness of breath and
			subjective fevers. CT chest on admission demonstrated bilateral
			ground glass opacities. Patient rapidly declined after an HD
			session to remove fluid, requiring intubation and ICU transfer,
			and was found to have ARDS and required vasopressor support.</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Patient was not a
				candidate for compassionate use remdesivir given ESRD</FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Therefore, was
					started on hydroxychloroquine </FONT>
					</P>
					<LI><P><FONT SIZE=2>Also given tocilizumab on hospital day 6 for
					continued hemodynamic instability and elevated inflammatory
					markers, including IL-6</FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Patient care is ongoing</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>56-year-old gentleman with ESRD since 2016
			secondary to IgA nephropathy, CAD for which he underwent PCI in
			2016, and heart failure with preserved ejection fraction of 52% on
			“optimal medical therapy” who traveled to South Korea in early
			January</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Descriptive studies are
			hypothesis-driven; therefore, cannot elucidate causation</FONT></P>
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Patients care remains
			ongoing, so clinical outcome is unknown</FONT></P>
			<P><FONT SIZE=2>Drug dosages were not provided</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: 0.18in; margin-right: 0.36in"><FONT SIZE=2><B>Michot
			JM, Albiges L, Chaput N, et al. Tocilizumab, an anti-IL6 receptor
			antibody, to treat Covid-19-related respiratory failure: a case
			report. </B></FONT><FONT SIZE=2><I><B>Ann Oncol. </B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does tocilizumab have efficacy in patients with
			SARS-CoV-2?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Patient clinically improved and rapidly became
			afebrile following tocilizumab. Oxygen requirements gradually
			decreased. CT chest showed partial improvement. CRP decreased from
			225 mg/L to 33 mg/L. </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Case study of a 42-year-old male with renal cler
			cell carcinoma who was admitted for a fever and bone pain.
			Developed a mild cough and was again febrile to 100.9 on hospital
			day 6, prompting a test for SARS-CoV-2 which returned positive. CT
			chest showed bilateral ground glass opacities. Was started on 5
			days lopinavir/ritonavir 400/100 mg on hospital day 7. Patient was
			dyspneic and desaturated on hospital day 8, requiring an increase
			in his supplemental oxygen from 2L/min to 6 L/min. He was
			subsequently treated with 2 doses of tocilizumab 8 mg/kg IV, 8
			hours apart.</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Improvement in clinical, radiologic, and
			laboratory endpoints</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>42-year-old gentleman with recent diagnosis of
			metastatic sarcomatoid clear cell renal cell carcinoma admitted
			for fever of 102.2, bone pain management, and treatment decision
			for malignancy. </FONT>
			</P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Descriptive studies are
			hypothesis-driven; therefore, cannot elucidate causation</FONT></P>
			<P><FONT SIZE=2>Drug dosing frequency was not provided</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: 0.18in; margin-right: 0.36in"><FONT SIZE=2><B>Mihai
			C, Dobrota R, Schroder M, et al. COVID-19 in a patient with
			systemic sclerosis treated with tocilizumab for SSc-ILD. </B></FONT><FONT SIZE=2><I><B>Ann
			Rheum Dis. </B></I></FONT><FONT SIZE=2><B>2020.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does tocilizumab have efficacy in patients with
			SARS-CoV-2?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Patient only developed a mild case of COVID-19,
			rather than a severe case, as is anticipated in a patient with ILD</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Case study of a
			57-year-old female with systemic sclerosis associated interstitial
			lung disease and symmetrical, non-erosive polyarthritis. </FONT>
			</P>
			<UL>
				<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Patient
				had been receiving tocilizumab: initially every 4 weeks for 3
				years, then moved to every 5 weeks</FONT></FONT></FONT></FONT></FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Clinical course</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Case study of a 57-year-old female with systemic
			sclerosis associated interstitial lung disease</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Descriptive studies are hypothesis-driven;
			therefore, cannot elucidate causation</FONT></P>
		</TD>
	</TR>
	<TR>
		<TD COLSPAN=2 WIDTH=100% VALIGN=TOP BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P ALIGN=CENTER STYLE="margin-left: 0.18in; margin-right: 0.36in"><FONT SIZE=2><B>Zhang
			X, Song K, Tong F, et al. First case of COVID-19 in a patient with
			multiple myeloma successfully treated with tocilizumab. </B></FONT><FONT SIZE=2><I><B>Blood
			Adv. </B></I></FONT><FONT SIZE=2><B>2020;4(7):1307-1310.</B></FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Question</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>Does tocilizumab have efficacy in patients with
			SARS-CoV-2?</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Findings</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Clinical improvement in
			one patient after initiating tocilizumab</FONT></P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Resolution of
				chest tightness </FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>CT chest obtained
				10 days after tocilizumab showed “ground glass opacities had
				obviously decreased” </FONT>
				</P>
				<LI><P><FONT SIZE=2>IL-6 level decreased to 57.87 pg/mL (7 days
				after) and rebounded to 117.1 pg/mL (14 days after tocilizumab;
				attributed to T-cell recovery)</FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Setting &amp; Design</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Case study of a
			60-year-old male from Wuhan, China with COVID-19, on maintenance
			therapy for multiple myeloma received tocilizumab for ongoing
			chest tightness, non-improvement on CT chest, and an IL-6 level of
			121.59. </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Found
				to be positive for SARS-CoV-2 on day 4 of admission. Was admitted
				for chest tightness without associated fever or cough; CT chest
				showed multiple ground-glass opacities and patient was started on
				3L nasal cannula.</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Labs:
				lymphopenic at 0.89, IL-6 121.59 pg/mL, D-dimer 0.31 mg/L</FONT></FONT></FONT></FONT></FONT></P>
				<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Revcieved:</FONT></FONT></FONT></FONT></FONT></P>
				<UL>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Umifenovir
					200 mg PO TID started on day 4 and continued for an unstated
					duration</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P STYLE="margin-bottom: 0in"><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Methylprednisolone
					40 mg IV q24h x 5 days (started on day 2 of admission)</FONT></FONT></FONT></FONT></FONT></P>
					<LI><P><FONT COLOR="#00000a"><FONT FACE="Calibri, serif"><FONT SIZE=3><FONT FACE="Arial, serif"><FONT SIZE=2>Tocilizumab
					8 mg/kg IV x 1 (given on day 9 of admission)</FONT></FONT></FONT></FONT></FONT></P>
				</UL>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Outcome</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Improvement in: </FONT>
			</P>
			<UL>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>Clinical features:
				Body temperature, oxygen saturations </FONT>
				</P>
				<LI><P STYLE="margin-bottom: 0in"><FONT SIZE=2>CT scan:
				Resolution of ground-glass opacities, focal consolidations</FONT></P>
				<LI><P><FONT SIZE=2>Laboratory: IL-6</FONT></P>
			</UL>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Patient Population</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2>60-year-old gentleman on maintenance therapy for
			multiple myeloma</FONT></P>
		</TD>
	</TR>
	<TR VALIGN=TOP>
		<TD WIDTH=15% BGCOLOR="#d9d9d9" STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P><FONT SIZE=2><B>Limitations</B></FONT></P>
		</TD>
		<TD WIDTH=85% STYLE="border: 1px solid #00000a; padding-top: 0in; padding-bottom: 0in; padding-left: 0.08in; padding-right: 0.08in">
			<P STYLE="margin-bottom: 0in"><FONT SIZE=2>Descriptive studies are
			hypothesis-driven; therefore, cannot elucidate causation</FONT></P>
			<P><FONT SIZE=2>Patients was late in disease course (hospital day
			9, illness day 24), so it is difficult to distinguish drug effect
			from natural history</FONT></P>
		</TD>
	</TR>
</TABLE>
</details>



<!-- =========================== REFERENCES ====================== -->
<br><br>

<details id="references">
<summary>
<h2>References >>> </h2>
</summary>

<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>1.	Chen Z, Hu J, Zhang Z, et al. Efficacy of
hydroxychloroquine in patients with COVID-19: results of a randomized
clinical trial. </FONT><FONT SIZE=2><I>medRxiv.
</I></FONT><FONT SIZE=2>2020:2020.2003.2022.20040758.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>2.	CHEN Jun LD, LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING
Yun,HUANG Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN
Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in
treatment of patients with common coronavirus disease-19 (COVID-19).
</FONT><FONT SIZE=2><I>J Zhejiang Univ (Med Sci). </I></FONT><FONT SIZE=2>2020;49(1):0-0.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>3.	Hong W. Combating COVID-19 with Chloroquine. </FONT><FONT SIZE=2><I>J
Mol Cell Biol. </I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>4.	Gao J, Tian Z, Yang X. Breakthrough: Chloroquine
phosphate has shown apparent efficacy in treatment of COVID-19
associated pneumonia in clinical studies. </FONT><FONT SIZE=2><I>Biosci
Trends. </I></FONT><FONT SIZE=2>2020;14(1):72-73.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>5.	Wang M, Cao R, Zhang L, et al. Remdesivir and
chloroquine effectively inhibit the recently emerged novel
coronavirus (2019-nCoV) in vitro. </FONT><FONT SIZE=2><I>Cell Res.
</I></FONT><FONT SIZE=2>2020;30(3):269-271.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>6.	Barnard DL, Day CW, Bailey K, et al. Evaluation of
immunomodulators, interferons and known in vitro SARS-coV inhibitors
for inhibition of SARS-coV replication in BALB/c mice. </FONT><FONT SIZE=2><I>Antivir
Chem Chemother. </I></FONT><FONT SIZE=2>2006;17(5):275-284.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>7.	Burkard C, Verheije MH, Wicht O, et al. Coronavirus
Cell Entry Occurs through the Endo-/Lysosomal Pathway in a
Proteolysis-Dependent Manner. </FONT><FONT SIZE=2><I>PLOS Pathogens.
</I></FONT><FONT SIZE=2>2014;10(11):e1004502.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>8.	de Wilde AH, Jochmans D, Posthuma CC, et al.
Screening of an FDA-approved compound library identifies four
small-molecule inhibitors of Middle East respiratory syndrome
coronavirus replication in cell culture. </FONT><FONT SIZE=2><I>Antimicrob
Agents Chemother. </I></FONT><FONT SIZE=2>2014;58(8):4875-4884.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>9.	Keyaerts E, Li S, Vijgen L, et al. Antiviral activity
of chloroquine against human coronavirus OC43 infection in newborn
mice. </FONT><FONT SIZE=2><I>Antimicrob Agents Chemother.
</I></FONT><FONT SIZE=2>2009;53(8):3416-3421.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>10.	Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M.
In vitro inhibition of severe acute respiratory syndrome coronavirus
by chloroquine. </FONT><FONT SIZE=2><I>Biochem Biophys Res Commun.
</I></FONT><FONT SIZE=2>2004;323(1):264-268.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>11.	Kono M, Tatsumi K, Imai AM, Saito K, Kuriyama T,
Shirasawa H. Inhibition of human coronavirus 229E infection in human
epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK
and ERK. </FONT><FONT SIZE=2><I>Antiviral Res. </I></FONT><FONT SIZE=2>2008;77(2):150-152.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>12.	Takano T, Katoh Y, Doki T, Hohdatsu T. Effect of
chloroquine on feline infectious peritonitis virus infection in vitro
and in vivo. </FONT><FONT SIZE=2><I>Antiviral Res.
</I></FONT><FONT SIZE=2>2013;99(2):100-107.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>13.	Vincent MJ, Bergeron E, Benjannet S, et al.
Chloroquine is a potent inhibitor of SARS coronavirus infection and
spread. </FONT><FONT SIZE=2><I>Virol J. </I></FONT><FONT SIZE=2>2005;2:69-69.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>14.	Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a
less toxic derivative of chloroquine, is effective in inhibiting
SARS-CoV-2 infection in vitro. </FONT><FONT SIZE=2><I>Cell Discov.
</I></FONT><FONT SIZE=2>2020;6:16.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>15.	Yao X, Ye F, Zhang M, et al. In Vitro Antiviral
Activity and Projection of Optimized Dosing Design of
Hydroxychloroquine for the Treatment of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2). </FONT><FONT SIZE=2><I>Clin
Infect Dis. </I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>16.	Gautret P, Lagier JC, Parola P, et al.
Hydroxychloroquine and azithromycin as a treatment of COVID-19:
results of an open-label non-randomized clinical trial. </FONT><FONT SIZE=2><I>Int
J Antimicrob Agents. </I></FONT><FONT SIZE=2>2020:105949.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>17.	Gautret P, Lagier JC, Parola P, et al. Clinical and
microbiological effect of a combination of hydroxychloroquine and
azithromycin in 80 COVID-19 patients with at least a six-day follow
up: an observational study. 2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>18.	Molina JM, Delaugerre C, Goff JL, et al. No Evidence
of Rapid Antiviral Clearance or Clinical Benefit with the Combination
of Hydroxychloroquine and Azithromycin in Patients with Severe
COVID-19 Infection. </FONT><FONT SIZE=2><I>Médecine et Maladies
Infectieuses. </I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>19.	Arabi YM, Deeb AM, Al-Hameed F, et al. Macrolides in
critically ill patients with Middle East Respiratory Syndrome. </FONT><FONT SIZE=2><I>Int
J Infect Dis. </I></FONT><FONT SIZE=2>2019;81:184-190.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>20.	Holshue ML, DeBolt C, Lindquist S, et al. First Case
of 2019 Novel Coronavirus in the United States. </FONT><FONT SIZE=2><I>New
England Journal of Medicine. </I></FONT><FONT SIZE=2>2020;382(10):929-936.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>21.	Sheahan TP, Sims AC, Graham RL, et al.
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic
coronaviruses. </FONT><FONT SIZE=2><I>Sci Transl Med. </I></FONT><FONT SIZE=2>2017;9(396).</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>22.	Sheahan TP, Sims AC, Leist SR, et al. Comparative
therapeutic efficacy of remdesivir and combination lopinavir,
ritonavir, and interferon beta against MERS-CoV. </FONT><FONT SIZE=2><I>Nat
Commun. </I></FONT><FONT SIZE=2>2020;11(1):222.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>23.	de Wit E, Feldmann F, Cronin J, et al. Prophylactic
and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque
model of MERS-CoV infection. </FONT><FONT SIZE=2><I>Proc Natl Acad
Sci U S A. </I></FONT><FONT SIZE=2>2020;117(12):6771-6776.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>24.	Mulangu S, Dodd LE, Davey RT, et al. A Randomized,
Controlled Trial of Ebola Virus Disease Therapeutics. </FONT><FONT SIZE=2><I>New
England Journal of Medicine. </I></FONT><FONT SIZE=2>2019;381(24):2293-2303.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>25.	Omrani AS, Saad MM, Baig K, et al. Ribavirin and
interferon alfa-2a for severe Middle East respiratory syndrome
coronavirus infection: a retrospective cohort study. </FONT><FONT SIZE=2><I>Lancet
Infect Dis. </I></FONT><FONT SIZE=2>2014;14(11):1090-1095.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>26.	Al-Tawfiq JA, Momattin H, Dib J, Memish ZA.
Ribavirin and interferon therapy in patients infected with the Middle
East respiratory syndrome coronavirus: an observational study. </FONT><FONT SIZE=2><I>Int
J Infect Dis. </I></FONT><FONT SIZE=2>2014;20:42-46.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>27.	Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin
and Interferon Therapy for Critically Ill Patients With Middle East
Respiratory Syndrome: A Multicenter Observational Study. </FONT><FONT SIZE=2><I>Clin
Infect Dis. </I></FONT><FONT SIZE=2>2019.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>28.	Chu CM, Cheng VC, Hung IF, et al. Role of
lopinavir/ritonavir in the treatment of SARS: initial virological and
clinical findings. </FONT><FONT SIZE=2><I>Thorax. </I></FONT><FONT SIZE=2>2004;59(3):252-256.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>29.	Zhao Z, Zhang F, Xu M, et al. Description and
clinical treatment of an early outbreak of severe acute respiratory
syndrome (SARS) in Guangzhou, PR China. </FONT><FONT SIZE=2><I>J Med
Microbiol. </I></FONT><FONT SIZE=2>2003;52(Pt 8):715-720.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>30.	Deng L, Li C, Zeng Q, et al. Arbidol combined with
LPV/r versus LPV/r alone against Corona Virus Disease 2019: A
retrospective cohort study. </FONT><FONT SIZE=2><I>J Infect. </I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>31.	Chan KS, Lai ST, Chu CM, et al. Treatment of severe
acute respiratory syndrome with lopinavir/ritonavir: a multicentre
retrospective matched cohort study. </FONT><FONT SIZE=2><I>Hong Kong
Med J. </I></FONT><FONT SIZE=2>2003;9(6):399-406.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>32.	Chan JF, Yao Y, Yeung ML, et al. Treatment With
Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV
Infection in a Nonhuman Primate Model of Common Marmoset. </FONT><FONT SIZE=2><I>J
Infect Dis. </I></FONT><FONT SIZE=2>2015;212(12):1904-1913.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>33.	Cao B, Wang Y, Wen D, et al. A Trial of
Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19.
</FONT><FONT SIZE=2><I>New England Journal of Medicine. </I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>34.	Young BE, Ong SWX, Kalimuddin S, et al.
Epidemiologic Features and Clinical Course of Patients Infected With
SARS-CoV-2 in Singapore. </FONT><FONT SIZE=2><I>JAMA. </I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>35.	Chen F, Chan KH, Jiang Y, et al. In vitro
susceptibility of 10 clinical isolates of SARS coronavirus to
selected antiviral compounds. </FONT><FONT SIZE=2><I>J Clin Virol.
</I></FONT><FONT SIZE=2>2004;31(1):69-75.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>36.	Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease
inhibitor nelfinavir inhibits replication of SARS-associated
coronavirus. </FONT><FONT SIZE=2><I>Biochem Biophys Res Commun.
</I></FONT><FONT SIZE=2>2004;318(3):719-725.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>37.	Wu C, Chen X, Cai Y, et al. Risk Factors Associated
With Acute Respiratory Distress Syndrome and Death in Patients With
Coronavirus Disease 2019 Pneumonia in Wuhan, China. </FONT><FONT SIZE=2><I>JAMA
Internal Medicine. </I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>38.	Chen N, Zhou M, Dong X, et al. Epidemiological and
clinical characteristics of 99 cases of 2019 novel coronavirus
pneumonia in Wuhan, China: a descriptive study. </FONT><FONT SIZE=2><I>Lancet.
</I></FONT><FONT SIZE=2>2020;395(10223):507-513.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>39.	Huang C, Wang Y, Li X, et al. Clinical features of
patients infected with 2019 novel coronavirus in Wuhan, China.
</FONT><FONT SIZE=2><I>Lancet. </I></FONT><FONT SIZE=2>2020;395(10223):497-506.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>40.	Arabi YM, Mandourah Y, Al-Hameed F, et al.
Corticosteroid Therapy for Critically Ill Patients with Middle East
Respiratory Syndrome. </FONT><FONT SIZE=2><I>Am J Respir Crit Care
Med. </I></FONT><FONT SIZE=2>2018;197(6):757-767.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>41.	Stockman LJ, Bellamy R, Garner P. SARS: systematic
review of treatment effects. </FONT><FONT SIZE=2><I>PLoS Med.
</I></FONT><FONT SIZE=2>2006;3(9):e343.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>42.	Lansbury L, Rodrigo C, Leonardi-Bee J,
Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in
the treatment of influenza. </FONT><FONT SIZE=2><I>Cochrane Database
Syst Rev. </I></FONT><FONT SIZE=2>2019;2:Cd010406.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>43.	Ferrey AJ, Choi G, Hanna RM, et al. A Case of Novel
Coronavirus Disease 19 in a Chronic Hemodialysis Patient Presenting
with Gastroenteritis and Developing Severe Pulmonary Disease. </FONT><FONT SIZE=2><I>Am
J Nephrol. </I></FONT><FONT SIZE=2>2020:1-6.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>44.	Michot JM, Albiges L, Chaput N, et al. Tocilizumab,
an anti-IL6 receptor antibody, to treat Covid-19-related respiratory
failure: a case report. </FONT><FONT SIZE=2><I>Ann Oncol. </I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>45.	Mihai C, Dobrota R, Schroder M, et al. COVID-19 in a
patient with systemic sclerosis treated with tocilizumab for SSc-ILD.
</FONT><FONT SIZE=2><I>Ann Rheum Dis. </I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>46.	Zhang X, Song K, Tong F, et al. First case of
COVID-19 in a patient with multiple myeloma successfully treated with
tocilizumab. </FONT><FONT SIZE=2><I>Blood Adv. </I></FONT><FONT SIZE=2>2020;4(7):1307-1310.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>47.	Colson P, Rolain JM, Raoult D. Chloroquine for the
2019 novel coronavirus SARS-CoV-2. </FONT><FONT SIZE=2><I>Int J
Antimicrob Agents. </I></FONT><FONT SIZE=2>2020;55(3):105923.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>48.	Warren TK, Jordan R, Lo MK, et al. Therapeutic
efficacy of the small molecule GS-5734 against Ebola virus in rhesus
monkeys. </FONT><FONT SIZE=2><I>Nature. </I></FONT><FONT SIZE=2>2016;531(7594):381-385.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>49.	Morse JS, Lalonde T, Xu S, Liu WR. Learning from the
Past: Possible Urgent Prevention and Treatment Options for Severe
Acute Respiratory Infections Caused by 2019-nCoV. </FONT><FONT SIZE=2><I>Chembiochem.
</I></FONT><FONT SIZE=2>2020;21(5):730-738.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>50.	Totura AL, Bavari S. Broad-spectrum coronavirus
antiviral drug discovery. </FONT><FONT SIZE=2><I>Expert Opin Drug
Discov. </I></FONT><FONT SIZE=2>2019;14(4):397-412.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>51.	Tocilizumab. Lexi-Drugs. Hudson, OH: Lexicomp, 2015.
<A HREF="http://online.lexi.com">http://online.lexi.com</A>. Accessed
March 8, 2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>52.	Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall
RS, Manson JJ. COVID-19: consider cytokine storm syndromes and
immunosuppression. </FONT><FONT SIZE=2><I>Lancet. </I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>53.	Xu X, Han M, Li T, et al. Effective Treatment of
Severe COVID-19 Patients with Tocilizumab. In: </FONT><FONT SIZE=2><I>ChinaXiv:
20200300026.</I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-left: 0.5in; text-indent: -0.5in; margin-bottom: 0in">
<FONT SIZE=2>54.	Zhou F, Yu T, Du R, et al. Clinical course and risk
factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: a retrospective cohort study. </FONT><FONT SIZE=2><I>Lancet.
</I></FONT><FONT SIZE=2>2020.</FONT></P>
<P STYLE="margin-bottom: 0in"><BR>
</P>

</details>



</BODY>
</HTML>
